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ABSTRACT 
 Colorectal cancer is the third leading cause of cancer-related mortality.  
Much progress has been achieved in combating this disease with surgical resection and 
chemotherapy in combination with targeted drugs.  However, most metastatic patients 
develop drug resistance so new modalities of treatment are needed. 
Notch signaling plays a vital role in intestinal homeostasis, self-renewal, and cell 
fate decisions during post-development and is activated in colorectal adenocarcinomas.  
Under debate is its role in carcinomas and metastatic disease.  In theory, blocking 
Notch activation using gamma-secretase inhibitors (GSIs) may show efficacy alone or in 
combination with chemotherapy in the treatment of colon cancer. 
In Chapter Three, we tested the capacity for GSIs to synergize with oxaliplatin in 
colon cancer cell lines and evaluated the underlying molecular mechanisms.  GSI alone 
had no effect on colon cancer cell lines.  Surprisingly, we show that GSIs blocked 
oxaliplatin-induced apoptosis through increased protein levels of the anti-apoptotic Bcl-2 
proteins Mcl-1 and/or Bcl-xL.  Restoration of apoptosis was achieved by blocking Mcl-1 
and/or Bcl-xL with obatoclax (an anti-apoptotic Bcl-2 agonist) or siRNA.  An unexpected 
result was the induction of cell death with the combination of GSI and obatoclax. 
In Chapter Four, we examined the mechanism of GSI + obatoclax-mediated cell 
death.  We found that apoptosis played a minimal role.  Rather, we identified blockage 
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of cytoprotective autophagy played a causative role.  Interestingly, we also saw 
autophagy induction in GSI-treated cells, which could explain the insensitivity of colon 
cancer cells to GSI.  When autophagy was blocked in GSI-treated cells, cells became 
sensitive to GSI and cell death was elicited.  The mechanism by which induction of 
autophagy occurs in GSI- treated cells is an area for further research.  
Overall, our work questions the validity of the use of GSIs in the treatment of 
colorectal cancers.  We show that GSIs may block apoptosis and induce cytoprotective 
autophagy simultaneously, resulting in increased drug resistance and cellular survival.  
Whether these two cellular survival processes occurs in patients needs to be examined 
before GSIs can be utilized in a clinical setting.  If so, these two hurdles must be 
overcome. 
  1 
CHAPTER ONE: INTRODUCTION 
Cancer 
Cancer comprises of a diverse and complex range of diseases caused by both 
intrinsic (such as germline or somatic mutations, epigenetics, and hormones) and 
extrinsic (such as cigarette smoke, ionizing radiation, and chemical carcinogens) 
factors.  The lifetime risk of developing cancer is 1 in 2 for both men and women in the 
United States, accounting for an estimated 1.6 million new cases per year (Siegel et al. 
2013).  One in 4 deaths is due to cancer, making it the seconding leading cause of 
death following heart disease (Howlader et al. 2013).  Cancer can originate at any site 
in the body, with the lungs, prostate, breast, and colon leading the pack.  The road to 
cancer development is a multi-step and multi-lateral process involving multiple 
molecular pathways within the cell that transforms a normal cell into a malignant one.  
The classical “Hallmarks of Cancer” include self-sufficiency in growth signals, 
insensitivity to anti-growth signals, cell-death evasion, limitless replicative potential, 
angiogenesis, and tissue invasion and metastasis, with this list being recently updated 
to also include reprogramming of metabolic pathways, immune system evasion, 
chromosomal abnormalities and DNA instability, and inflammation (Hanahan et al. 
2000; Hanahan et al. 2011).  While substantial progress has been made in the 
prevention and treatment of cancer, the heterogeneity and plasticity of cancer cells has 
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impeded effective long-term strategies to manage or ‘cure’ many cancer types.  
Targeted molecular therapy, alone or in combination with conventional chemotherapy 
and/or other targeted therapies, has therefore been the current focus of medical 
research. 
 
Colorectal Cancer 
Colorectal cancer accounts for more than 50,000 deaths each year in the United 
States and remains the third leading cause of cancer-related mortality (Siegel et al. 
2013).  While surgical resection remains the gold standard of treatment for localized 
disease, chemotherapy combinations with oxaliplatin, irinotecan, 5-fluorouracil, the 
VEGF inhibitor bevacizumab, and EGFR inhibitors have led to significant improvements 
in survival at all stages (Saltz 2009; Garcia-Foncillas et al. 2010).  However, most 
metastatic colorectal cancer patients eventually develop drug resistance to current 
therapies so new strategies are needed for treatment and improved survival of these 
patients. 
 
Colon Architecture 
 Normal human colon has millions of self-renewing crypts, each containing around 
2000 cells (Cheng et al. 1984; Potten et al. 1992).  The crypt is maintained by a small 
population of stem cells located at or near the base of the crypt; they divide slowly and 
gives rise to transit-amplifying progenitor cells (Figure 1).  These progenitor cells have a 
very limited capacity to self-renew; within three to four divisions they terminally 
differentiate into one of the mature epithelial lineages – absorptive 
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colonocytes/enterocytes, hormone-secreting enteroendocrine cells, and mucus-
producing goblet cells (Potten et al. 1997).  The differentiated cells migrate towards the 
surface of the colon where they die and are shed into the lumen.  All the cells of the 
crypt, except the stem cell, are regenerated every 5-7 days (Barker et al. 2008). 
 
 
Figure 1: Architecture of the Colon Crypt 
In the colon, stem cells are thought to reside at the base of the colon crypt and give rise 
to transit-aplifying progenitor cells.  These transit-amplifying cells then terminally 
differentiate into either colonocytes, enteroendocrine cells, or goblet cells.  Reprinted by 
permission from Nature Publishing Group (McDonald et al. 2006). 
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Figure 2: Sequence of Events to Colorectal (Adenoma:Carcinoma) Cancer 
Mutations in the APC gene are considered to be an early event in colon carcinogenesis.  
Subsequent activation of oncogenes and repression of tumor suppressor genes, along 
with increasing genetic instability, leads to progression and development of 
adenocarcinoma.  Reprinted by permission from Nature Publishing Group (McDonald et 
al. 2006). 
Colorectal (Colon) Carcinogenesis 
 Dr. Bert Vogelstein introduced a multi-step model of colon carcinogenesis in 
1988 (Figure 2).  Mutations in the APC (adenomatous polyposis coli) gene are 
considered to be one of the earliest events in this process, occurring in up to 80% of 
sporadic colorectal carcinomas (Vogelstein et al. 1988).  The APC tumor-suppressor 
protein downregulates the Wnt/β-catenin pathway, leading to increased cell proliferation 
and inhibition of cell death (He et al. 2004; Gregorieff et al. 2005).  Further mutations in 
K-RAS, SMADs, and TP53 can occur during colorectal cancer progression.  More 
recently, chromosomal instability (CIN) and microsatellite instability (MSI) have been 
described as distinct molecular mechanisms that give rise to colorectal cancer, each 
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displaying unique molecular features.  Other pathways that drive carcinogenesis include 
Notch, TFG-β, EGFR, and PI3K signaling (Pritchard et al. 2011). 
 
The Notch Pathway 
 The Notch pathway is an evolutionarily conserved pathway important in cell 
differentiation, proliferation, apoptosis, cell fate decisions, and stem cell renewal during 
development and cancer.  The Notch receptor is a heterodimeric type 1 single-pass 
transmembrane protein that undergoes a series of proteolytic cleavage steps to form a 
mature receptor (Figure 3).  There are four Notch family proteins (Notch1-4) that begin 
as a ~300 kDa precursor protein.  The protein is shuttled to the trans-Golgi 
compartment where it is cleaved by furin-like convertases, generating N- and C-terminal 
fragments (NTF and CTF), which are subsequently joined by noncovalent bonds 
(Blaumueller et al. 1997; Logeat et al. 1998; Rand et al. 2000).  The NTF also becomes 
heavily glycosylated to ensure proper folding and facilitate ligand binding (Vodovar et al. 
2008).  The mature receptor is then exported to the cell surface.  Notch signaling begins 
with binding of the NTF to one of its five ligands (Jagged 1-2 and Delta-like 1, 3, and 4) 
located on adjacent cells, allowing for exposure of the second cleavage site on the 
extracellular portion of the CTF by TACE/ADAM metalloproteases (Brou et al. 2000; 
Mumm et al. 2000).  This generates a membrane-anchored activated Notch form 
termed Notch extracellular truncation (NEXT).  NEXT is then swiftly cleaved at a third 
site by gamma-secretase, an intramembrane aspartyl protease complex, releasing the 
Notch IntraCellular Domain (NICD) (Schroeter et al. 1998; De Strooper et al. 1999).   
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Figure 3: Overview of Notch Receptor Synthesis and Signaling 
The precursor Notch protein is cleaved by furin-like convertases in the trans-Golgi 
compartment to produce an N-terminal extracellular fragment and a C-terminal 
transmembrane fragment.  These two fragments are joined through noncovalent linkage 
to form the mature heterodimeric receptor and shuttled to the cell surface.  Notch 
signaling is initiated through binding of its receptor to its ligand located on an adjacent 
cell, allowing for exposure of the second cleavage site by TACE/ADAM metalloprotease 
followed by intramembranous cleavage at a third site by gamma-secretase.  Cleavage 
by gamma-secretase releases the Notch IntraCellular Domain (NICD).  NICD 
translocates to the nucleus, binds to the transcription factor CSL (CBF-1), displaces The 
intracellular activated form of Notch, NICD, translocates to the nucleus and binds to 
various corepressors, and recruits MAML-1 and p300/CBP to initiate transcription of 
Notch target genes.  Reprinted by permission from Elsevier (Fortini 2009). 
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The transcriptional factor CSL (CBF-1/suppressor of hairless/Lag-1), displacing various 
co-repressors and recruiting MAML-1 (mastermind-like-1) and p300/CBP to induce 
transcription (Tamura et al. 1995; Fryer et al. 2002; Wallberg et al. 2002).  Notch target 
genes include the HES (hairy/enhancer of split) and HEY family members, c-myc, p21, 
and cyclin D1, to name a few (Jarriault et al. 1995; Borggrefe et al. 2009). 
 
Gamma-Secretase Complex 
 Gamma-secretase is a multiprotein transmembrane complex consisting of at 
least 4 core components: presenilin (PSEN), Pen-2, nicastrin (NCT), and Aph-1 (Figure 
4).  The complex catalyzes the intramembranous cleavage of type I transmembrane 
proteins such as APP (amyloid precursor protein, implicated in the development of 
Alzheimer’s Disease), Notch, E-cadherin, ErbB4, CD44, and c-Met (for review, see 
(Haapasalo et al. 2011)).  Presenilin1, an aspartyl type protease, is the catalytic domain 
of gamma-secretase and contains nine transmembrane domains (Wolfe et al. 1999; 
Laudon et al. 2005).  Nicastrin is another type I integral membrane protein (Yu et al. 
2000).  Aph-1 has 7 transmembrane domains while Pen-2 has two (Francis et al. 2002; 
Goutte et al. 2002).  All four proteins are necessary and sufficient for gamma-secretase 
activity (Kimberly et al. 2003; Takasugi et al. 2003).  Nicastrin is essential for stability of 
the complex; NCT-null mouse fibroblasts retain on 50% gamma-secretase activity 
compared to wildtype but the trimeric complex is highly unstable (Zhao et al. 2010).  
Aph-1 is also important to regulate stability (LaVoie et al. 2003).  Pen-2 also increases 
stability of the complex and may contribute to the proteolytic activity of the complex 
(Bammens et al. 2011).  More than 50 additional proteins are thought to associate with 
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gamma-secretase, regulating its activity, subcellular localization, and substrate 
specificity (Chen et al. 2002; McCarthy et al. 2009) 
 
  
Figure 4: Schematic of Gamma-secretase Assembly and Activation 
The gamma-secretase complex consists of at least four core proteins: Presenilin 
(PSEN), Pen-2, Nicastrin (NCT), and Aph-1.  Presenilin is the catalytic domain of the 
complex but is highly unstable and rapidly degraded.  Binding of NCT and Aph-1 to 
Presenilin help stabilize the complex.  Finally, binding of Pen-2, while also potentially 
increasing stability, contributes to the proteolytic activity of the mature complex.  
Reprinted by permission from Nature Publishing Group (Takasugi et al. 2003). 
Notch Signaling: Oncogenic and Tumor-Suppressive 
Aberrant activation of Notch signaling has been implicated in a variety of solid 
tumors, including breast (Reedijk et al. 2005; Stylianou et al. 2006), melanoma (Bedogni 
et al. 2008), ovarian (Wang et al. 2010), and prostate (Santagata et al. 2004; Wang et 
al. 2010).  It was first linked to T-cell acute lymphoblastic leukemia (T-ALL), where 
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>50% of tumors harbored activating mutations within Notch1 (Ellisen et al. 1991; Weng 
et al. 2004).  In contrast, reduced Notch signaling has been implicated in HPV-positive 
cervical cancer (Talora et al. 2002), neuroendocrine tumors (Kunnimalaiyaan et al. 
2007), small cell lung cancer (Sriuranpong et al. 2001), hepatocellular carcinoma (Qi et 
al. 2003), and skin squamous cell carcinoma (Lefort et al. 2007).  Indeed, the use of 
gamma-secretase inhibitors in clinical trials for Alzheimer’s Disease (the amyloid 
precursor protein – APP –implicated in this disease is a gamma-secretase target) 
showed an increase risk of skin cancer development (McKee); decreased gamma-
secretase activity is also associated with increased skin cancer occurrence in mice (Li 
et al. 2007).  Therefore, the biological outcome/function of Notch signaling as oncogenic 
or tumor-suppressive is highly cell context specific (reviewed in (Radtke et al. 2003; 
Leong et al. 2006)). 
 
Notch Signaling in Normal Colon 
 The Notch pathway is one signaling pathway that plays a major role in 
homeostasis of the colon crypt compartment (Radtke et al. 2005).  One function is to 
maintain the intestinal stem/progenitor cells; these are the cells that express Notch 
receptors and downstream target genes (Schroder et al. 2002; Sander et al. 2004).  
Transgenic mice expressing NICD under the control of an intestine-specific Villin 
promoter exhibited significantly increased proliferation in crypt cells, impaired 
differentiation into goblet and enteroendocrine cells, and upregulated Hes1 (Fre et al. 
2005).  Deletion of CSL by cre-mediated recombination in the intestinal epithelium of 
mice revealed a massive differentiation of the proliferative transit-amplifying cells into 
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goblet cells; similar phenotypic results were obtained by blocking Notch signaling with a 
gamma-secretase inhibitor in mice with normal colons and in adenomas arising in 
ApcMin mice (van Es et al. 2005).  These findings are consistent with observations in 
HES1-null mice and rats treated with gamma-secretase inhibitors showing goblet cells 
metaplasia (Jensen et al. 2000; Milano et al. 2004). 
 
Aberrant Activation of Notch Signaling in Colon Cancer 
The Notch pathway has been implicated in colon cancer tumorogenesis.  
Colorectal cancer tumors in humans show higher expression of NOTCH1, JAGGED 
ligands, and HES1 compared to normal by in situ hybridization and qPCR (Reedijk et al. 
2008; Qiao et al. 2009).  Transgenic expression of NICD in ApcMin mice, which form 
multiple adenomas (but do not progress into carcinoma), show increased number of 
adenomas, suggesting that Notch signaling may play a role in initiation but not 
progression of intestinal tumors (Fre et al. 2009).  This group also showed elevated 
levels of Notch-1 and Hes-1 in adenomas compared to carcinomas in a small cohort of 
human patients.  These finding are consistent with other studies in humans showing 
high Notch signaling in adenomas and early-stage colon carcinomas but low in later-
stage, advanced and metastatic colon carcinomas (Reedijk et al. 2008; Rodilla et al. 
2009).  The molecular mechanisms underlying this distinction remain unclear. 
 
Apoptosis 
 Apoptosis is an evolutionarily conserved multi-step form of type I programmed 
cell death that culminates in the self-destruction of a cell.  This process is important in 
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normal development, aging, and tissue homeostasis by removing damaged or 
redundant cells.  For example, cells in the bone marrow and intestine undergo 
apoptosis to make way for new cells every day.  The deregulation of apoptosis is 
associated with disease: increased apoptosis in neurodegenerative disorder and 
inhibition of apoptosis in cancer, for example (Thompson 1995). 
 The morphological and biochemical features that characterize apoptosis include 
cell shrinkage, membrane blebbing, chromosome condensation, nuclear fragmentation, 
mitochondrial membrane disruption, activation of caspases, and exposure of 
phosphatidylserine (PS) on the outer leaflet of the plasma membrane (Kerr et al. 1972; 
Martin et al. 1995; Saraste et al. 2000).  The resultant apoptotic cell is removed by 
phagocytosis, providing the engulfing cell with recyclable cellular material while avoiding 
inflammation. 
 Apoptosis can be triggered by two pathways: the extrinsic pathway or the intrinsic 
pathway.  The extrinsic pathway of apoptosis is activated upon binding of a specific 
ligand to death receptors.  The intrinsic pathway is activated by cellular stress and 
involves the mitochondria.  Apoptosis is tightly regulated and leads to the execution of 
step-wise caspase activation.  Caspases, cysteinyl aspartate-specific proteases, are 
synthesized as inactive precursors known as procaspases and are activated upon 
cleavage.  They can be separated into two functional groups: initiator caspases 
(caspase-2, -8, -9, -10) and effector caspases (caspases-3, -6, -7) (Cohen 1997).  
Active caspases can then cleave other caspases to amplify the signal or cleave other 
proteins, resulting in the morphological and biochemical features of apoptosis (Enari et 
al. 1998; Coleman et al. 2001; Taylor et al. 2008). 
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Figure 5: The Intrinsic and Extrinsic Pathways of Apoptosis 
The extrinsic apoptotic pathway is activated upon binding of a specific ligand to death 
receptors and subsequent recruitment of cytoplasmic adaptor proteins and initiator 
procaspase-8 and/or -10.  The initiator procaspases are cleaved to produce mature, 
active caspase-8 and/or -10 that, in turn, cleave and activate effector caspase-3, -6, 
and/or -7.  The intrinsic pathway is initiated by extra- or intracellular stress, leading to 
activation of Bax and/or Bak at the mitochondria and subsequent cytochrome c release.  
Cytochrome c forms a complex with Apaf-1 and caspase-9 and this complex cleaves 
and activates effector caspase-3, -6, and/or -7.  Reprinted by permission from Nature 
Publishing Group (Ashkenazi 2008). 
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The Extrinsic Apoptotic Pathway 
 The extrinsic, or receptor-mediated, pathway involves activation of the tumor 
necrosis factor (TNF) family member receptors by their extracellular ligands (Figure 5).  
These receptors, often referred to as death receptors, all contain cysteine-rich 
extracellular domains responsible for ligand binding and a cytoplasmic death domain 
(DD).  Members include TRAIL, FasL, TNFR1-2, and DN3-5 (Locksley et al. 2001).  
Ligand binding initiates receptor trimerization and activation, leading to the recruitment 
of cytoplasmic adaptor proteins such as FADD (Fas-associated death domain) or 
TRADD (TNF-associated death domain) to the DD of the receptor (Ashkenazi et al. 
1998).  FADD also contains a death effector domain (DED) that recruits DED-containing 
initiator caspase-8 and/or caspase-10.  The resultant complex formed is termed death-
inducing signaling complex (DISC) and is responsible for proteolytic processing and 
activation of the initiator caspases leading to further cleaving and activation of the 
effector caspases (Ashkenazi 2002).  The apoptotic signal can be further amplified by 
cleavage of BID by caspase-8 into a truncated form (tBID).  This tBID protein 
translocates into the mitochondria and interacts with Bak and Bax to activate the 
intrinsic apoptotic pathway (Yin 2000). 
 
The Intrinsic Apoptotic Pathway 
 The intrinsic, or mitochondrial, pathway is activated by extracellular and 
intercellular stresses, including growth factor withdrawal, oxidative stress, hypoxia, 
radiation, and chemotherapy (Figure 5). 
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The members of Bcl-2 family tightly regulate apoptosis through the intrinsic 
pathway.  They can be divided into two classes: inhibitors of apoptosis and promoters of 
apoptosis.  Anti-apoptotic Bcl-2 members include Bcl-2, Bcl-xL, Mcl-1, and Bcl-w and 
share structural similarity within all four of their Bcl-2 homology (BH) domains.  Pro-
apoptotic Bcl-2 members can be further subdivided into multi-domain proteins, like Bax, 
Bak, and Bok, and into BH-3 only proteins, like Puma, Noxa, Bim, Bad, and Bid (Petros 
et al. 2004).  The anti-apoptotic members inhibit apoptosis by inhibiting Bax and Bak, 
thereby maintaining mitochondrial integrity.  The BH-3 only proteins act as stress 
sensors; two models have been proposed to explain how they promote apoptosis.  First, 
in the displacement model, the BH3-only proteins bind to anti-apoptotic Bcl-2 family 
members, releasing them from Bax and Bak.  In the second model, the BH-3 only 
proteins directly activate the multi-domain, pro-apoptotic proteins Bax and Bak (Strasser 
2005; Shamas-Din et al. 2011). 
Once Bax and Bak are dissociated from anti-apoptotic Bcl-2 proteins, they 
undergo a conformational change, translocate to the mitochondria, and oligomerize to 
form a pore (Hsu et al. 1998; Lalier et al. 2007).  This activation and subsequent pore 
formation is required for mitochondrial outer membrane permeabilization (MOMP) and 
results in the release of cytochrome c (and/or other apoptogenic proteins AIF, 
endonuclease G, HtrA2/Omi, and Smac/Diablo) into the cytoplasm.  There, cytochrome 
c binds to Apaf-1, causing Apaf-1 oligomerization and recruitment of procaspase-9 
(forming the apoptosome).  Procaspase-9 clustering in the apoptosome results in its 
cleavage to an activated form and subsequent cleavage of effector caspases.  
Smac/Diablo and HtrA2/Omi bind to inhibitors of apoptosis (IAP) proteins, such as XIAP 
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and cIAP, preventing their inhibition of effector caspases; AIF and endonuclease G 
participate in DNA fragmentation.  Initiation of the intrinsic apoptotic pathway is 
therefore a delicate balance between pro- and anti-apoptotic factors (Shore et al. 2005). 
 
Autophagy 
 Autophagy is an evolutionary conserved cellular pathway responsible for the 
degradation and recycling of cellular material and organelles.  Autophagy plays a role in 
stress responses (including nutrient deprivation, growth factor withdrawal, hypoxia, and 
chemotherapy) to promote survival, in cellular homeostasis to remove misfolded or 
aggregated proteins and damaged organelles, and during host-defense to degrade 
intracellular pathogens (Moreau et al. 2010). Three distinct forms of autophagy have 
been described: macroautophagy, microautophagy, and chaperone-mediated 
autophagy. 
 Autophagy plays a dual role in carcinogenesis.  On one hand, it’s believed to play 
a tumor suppressive role to limit tumor initiation.  However, once neoplastic lesions 
have been established, autophagy instead facilitates tumor progression and may be 
critical for continued growth and sustained cellular metabolism.  Autophagy is also 
induced in response to chemotherapy to limit drug efficacy.  Aberrant control of 
autophagy is now considered to be another hallmark of cancer (Levine et al. 2008; 
Kimmelman 2011). 
 Upon autophagy induction, a small vesicular sac called the isolation membrane 
or phagophore elongates and subsequently encloses a portion of the cytoplasm.  This 
results in the formation of a double-membrane structure, termed the autophagosome.  
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The autophagosome matures when the outer membrane fuses with a lysosome (to form 
the autolysosome), leading to the degradation of the enclosed materials together with 
the inner autophagosomal membrane by lysosomal hydrolases.  Amino acids and other 
small molecules that are generated by autophagic degradation are delivered back to the 
cytoplasm for recycling or energy production (Figure 6)(Yang et al. 2010).  
 
 
Figure 6: The Process of Autophagy 
Upon activation of autophagy by starvation or growth factor deprivation, for example, 
cytoplasmic material becomes enclosed in a double-membrane structure termed the 
autophagosome.  The lysosome fuses with the autophagosome and leads to the 
degradation of the enclosed cytoplasmic material.  The resultant amino acids and other 
small molecules generated can be used for energy-production or recycling.  Reprinted 
by permission from American Society of Clinical Investigation (Levine et al. 2005). 
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Figure 7: The Core Molecular Machinery of Autophagy 
There are three basic steps leading to autophagosome formation: initiation, vesicle 
nucleation, and vesicle elongation and closure.  Initiation begins when mTOR is 
inactivated, allowing for the formation of the ULK1 complex.  Vesicle nucleation begins 
by the formation of the Beclin1-Vsp34 PI3K-Atg14L-Vsp15 complex.  Vesicle elongation 
and closure follows via two conjugation systems: Atg12 and LC3.  They lead to the 
conjugation of phosphatidylethanolamine (PE) to LC3-1, forming the autophagic vesicle-
associated form (LC3-II).  Reprinted by permission from Elsevier (Rautou et al. 2010). 
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Core Molecular Machinery of Autophagy 
 As mentioned earlier, autophagy occurs at basal, constitutive levels in many cells 
and is upregulated under physiological stress.  The initiation of autophagy occurs mainly 
through downregulation of mTOR (target of rapamycin) signaling and the Vps34 (a class 
III phosphatidylinositol-3-kinase (PI3K)) – Atg6/Beclin-1 complex (Yang et al. 2010). 
 
ATG genes 
 The basic molecular machinery of autophagy involves many ATG (autophagy 
associated proteins) genes.  They were first identified in yeast and show strong 
evolutionary conservation from yeast to humans.  The Atg proteins regulate the entire 
process of autophagy initiation, maturation, and degradation of substrates.  They are 
divided into four core subgroups: 1) The Atg1/unk-51-like kinase (ULK1), 2) 
Vsp34/Beclin-1 (Atg6), 3) two ubiquitin-like proteins (Atg12 and Atg8/LC3) conjugation 
complexes, and 4) two transmembrane protein, Atg9 and VMP1 (vacuole membrane 
protein 1) (Figure 7). 
Atg1 exists in a complex with Atg13 and Atg7.  Atg13 is phosphorylated by 
mTOR signaling to modulate complex formation.  Initiation begins when mTOR 
becomes inactivated; Atg13 becomes dephosphorylated and increases Atg1-Atg7-
Atg13 complex formation, initiating autophagy.  Vesicle nucleation begins by formation 
of the autophagy-specific Vsp34-Beclin-1-Atg14L-Vsp15 complex.  Vsp15 (vacuolar 
sorting protein 15) (the yeast homologue of mammalian p150) is a protein kinase that 
activates Vsp34.  Vsp34 is a lipid kinase that generates phosphatidylinositol (3)-
phosphate (PtdIns(3)P) at the PAS (perivacuolar sites known as phagophore assembly 
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sites) to allow recruitment of other Atg proteins.  Agt14L is thought to direct the complex 
to the phagophore and also initiate recruitment of other Atg proteins (Yang et al. 2010).  
The nucleation step can be blocked by treatment with the PI3K inhibitor 3-MA (3-
methyladenine). 
The two ubiquitin-like conjugation systems, Atg12-Atg5 and Atg8/LC3-
phosphatidylethanolamine (PE), regulate the elongation and expansion of 
autophagosome formation.  Atg7 and Atg10 (E1 and E2-like enzymes, respectively), 
conjugate Atg12 to Atg5.  The Atg12-Atg5 complex non-covalently interacts with 
Atg16L.  The second system involves cleavage of Atg8/LC3 (microtubule-associated 
protein light chain 3) at its C terminus by Atg4.  This generates the cleavage product 
LC3-I, a cytosolic protein with a C-terminal glycine reside.  PE is conjugated to the 
glycine residue in a reaction that requires Atg7 and Atg3 (an E2-like enzyme).  This 
lipidated form of LC3 (LC3-II) is attached to both the outer and inner phagophore 
membrane.  Removal of LC3-II from the outer membrane of the autophagosome 
facilitates its fusion to the lysosome (Yang et al. 2009; Yang et al. 2010).  Upon 
completion, LC3-II is degraded within the autolysosome.  Monitoring of LC3-II levels is 
one of the best markers to assess autophagic flux (Rubinsztein et al. 2009). 
Mammalian Atg9 and VMP1 are two transmembrane proteins required for the 
biogenesis of autophagosomes and recruitment of the Vsp34-Beclin1-Atg14L-Vsp15 
complex to the phagophore, respectively.  Atg9 shuttles between the trans-Golgi 
network and late endosomes and peripheral sites.  This shuttling is cycling of Atg9 
localization is thought to contribute to the delivery of membranes to the forming 
autophagosome (Yang et al. 2010). 
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CHAPTER TWO: MATERIALS AND METHODS 
Cell Lines and Chemicals 
 The human colorectal cancer cell lines HCT-116, HCT-15, HT-29, and Colo205 
were obtained from NCI; SW480 was obtained from ATCC.  All cell lines were grown in 
RPMI 1640 supplemented with 10% FBS and L-glutamine and grown in a 37°C 
humidified camber 5% CO2.  Cells were maintained for no more than 30 passages after 
thawing and tested as mycoplasma-free.  HCT-116 and SW480 cell lines were 
authenticated using short tandem repeat (STR) DNA typing according to ATCC’s 
“Authentication of Human Cell Lines:  Standardization of STR Profiling” (2012). 
 Oxaliplatin (Sigma) was suspended in 5% dextrose.  The gamma-secretase 
inhibitors MRK-003 (a generous gift from Merck Inc), DAPT (N-[N-(3,5-
difluorophenacetyl-L-alanyl)-S-phenylglycine]-t-butyl ester; Santa Cruz), GSI-XII 
(Calbiochem), and GSI-XX (DBZ; Calbiochem) and the Bcl-2 inhibitor obatoclax (GX15-
070; Selleck) were suspended in DMSO.  3-MA (Santa Cruz) was suspended in water 
and dissolved by heating at 100°C.  Aliquots were stored at -20°C and reheated before 
use.  Bafilomycin A1 and z-VAD-FMK were purchased from Santa Cruz.  Propidium 
iodide and acridine orange were purchased from Sigma. 
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Apoptosis Assays via Flow Cytometry 
 Apoptosis was measured by flow cytometry by detecting activated Caspase-3.  
Cleaved Caspase-3 was measured using the Active Caspase3-FITC Apoptosis Assay 
Kit (BD# 550480) according to the manufacturer’s protocol.  Briefly, floating and 
adherent cells were collected, washed in PBS, and fixed in Cytofix/Cytoperm buffer for 
20 minutes on ice.  Cells were then washed in Perm/Wash buffer and incubated with 
Cleaved caspase3-FITC antibody for 30 minutes at room temperature.  Data were 
acquired on a FACS Scan or Calibur and analyzed with FlowJo software. 
 Apoptosis was also measured by AnnexinV-FITC (or AnnexinV-APC) (BD# 
556420 or 550475) and 7-AAD staining according to the manufacturer’s protocol.  
Adherent and non-adherent cells were collected and incubated in 1X Annexin-V Binding 
Buffer (10mM Hepes pH 7.4, 150mM NaCl, 2.5nM CaCl2) with AnnexinV-FITC (or 
AnnexinV-APC) and 7-AAD for 15 minutes at room temperature.  Data were acquired 
on a FACS Scan or Calibur and analyzed with FlowJo software.  Dot plots with the 
percentages of each quadrant were reported for each sample. 
 Apoptosis was also measured by Propidium iodide (PI) staining for cell viability.  
Cells were harvested by trypsinization and washed with PBS.  Cells were suspended in 
2 µg/ml PI in PBS and kept on ice.  Data were acquired on a FACS Scan or Calibur and 
analyzed with FlowJo software. 
 
Western Blotting 
 Cell pellets were lysed in standard RIPA buffer (50 mM Tris pH 7.4, 150 mM 
NaCl, 1% Igepal CA-630, 0.5% sodium deoxycholate, and 0.1% SDS) containing 
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protease and phosphatase inhibitors – 1 µg/ml each of aprotin, leupeptin, and pepstatin 
and 1 mM each of sodium fluoride, sodium vanadate, phenylmethylsulfonyl fluoride, and 
sodium pyrophosphate - for 30 minutes on ice.  Cell extracts were clarified by 
centrifugation at 15,000g for 10 minutes at 4°C.  Protein concentration was determined 
via the Bradford Assay and lysates were mixed 1:1 in 2X Laemmeli Sample Buffer and 
heated at 95°C for 5 minutes.  30 µg of protein was resolved onto SDS-PAGE gels and 
transferred onto PVDF membranes.  Membranes were blocked in 1X TBST (Tris 
buffered saline with 0.05% Tween-20) supplemented with 5% milk and primary 
antibodies were incubated overnight at 4°C in 1% BSA or 5% milk dissolved in TBST.  
Membranes were washed and incubated with peroxidase-conjugated anti-mouse or 
anti-rabbit IgG secondary antibodies (Jackson ImmunoReasearch Laboratories).  The 
signals were visualized using SuperSignal West Pico Chemiluminescent detection 
reagent (Pierce/ThermoScientific). 
 
Primary Antibodies 
 The primary antibodies used for western blot were: rabbit anti-Mcl-1 (#5453), 
rabbit anti-Bcl-xL (#2764), rabbit anti-PARP (#9542), rabbit anti-LC3A/B (#4599); rabbit 
anti-Atg5 (#8540), and rabbit anti-Beclin1 (#3495) from Cell Signaling; mouse anti-β-
actin (#A5441) from Sigma; and mouse anti-p62 (#sc-28359) from Santa Cruz. 
 
Cytochrome C Release 
 Adherent and non-adherent cells were harvested by scrapping and pelleted by 
centrifugation.  For preparation of cytosolic extracts, the cell pellet was immediately 
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suspended in a cytochrome c permeabilization buffer (20 mM Hepes pH 7.5, 10 mM 
KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 250 mM Sucrose) 
containing 200 µg/ml Digitonin (Sigma# D141) supplemented with protease and 
phosphatase inhibitors (see above in Western blotting) and incubated on ice for 5 
minutes.  Lysates were clarified by centrifugation at 1000g for 5 minutes at 4°C to 
remove unlysed cells, cell debris and nuclei.  The supernatant transferred to a new tube 
and centrifuged at 20,000xg for 20 minutes at 4°C to remove mitochondria and any 
remaining debris.  The supernatant was transferred to a new tube and 20-30 µg of 
protein was subjected to western blot analysis using anti-cytochrome c (BD# 556433) 
antibody.  An anti-COX IV (Cell Signaling# 4580) antibody was used as a control to 
measure mitochondrial contamination of cytosolic extracts. 
 
Cell Survival and Colony Formation Assays 
 Short-term cell survival was measured by MTT assay.  Cells were seeded into 
96-well plates in quadruplicate and drug treated the next day for 48 hours.  MTT ((3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Sigma# M2128) was added 
at a final concentration of 0.5 µg/uL per well and incubated for 3-4 hours in a humidified 
chamber at 37°C in the dark.  The plate was centrifuged, supernatant aspirated, 100 µL 
/ well of DMSO added, and the absorbance measured at 540 nm.  Data were 
normalized relative to untreated controls, which were taken as 100% survival. 
 Colony / foci formation assays were used to assess long-term cell survival.  Cells 
were seeded into 12-well plates, allowed to attach overnight, and drug treated for 24 
hours.  Attached cells were then trypsinized, counted, and 1000 cells were plated in 
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triplicate in 6-well plates and allowed to grow for 8 or 12 days.  Cells were fixed with 4% 
paraformaldehyde for 15 minutes with 0.1% crystal violet. 
 
Cell Cycle Analysis 
 Adherent and non-adherent cells were collected, fixed in ice-cold 70% ethanol, 
and kept at 4°C overnight.  Cells were then stained with 20 µg/ml propidium iodine, 200 
µg/ml RNase A, and 0.1% Triton X-100 in PBS for 30 minutes in the dark at room 
temperature.  Data was acquired on a FACS Scan or Calibur and analyzed with ModFit 
software.   
 
Activation of Bax and Bak 
 Cell pellets were lysed in CHAPS lysis buffer (1% CHAPS, 150 mM NaCl, 1 mM 
Hepes pH7.4) containing protease and phosphatase inhibitors (see above for details) 
for one hour on ice.  Lysates were centrifuged and protein concentration was 
determined by Bradford assay.  500 µg of protein was precleared with 20 µL of anti-
Mouse IgG (whole molecule)-Agarose beads (Sigma# A6531) for one hour at 4°C with 
rotation.  The beads were pelleted and the supernatant was transferred to a new tube.  
Activated Bax or Bak was immunoprecipitated with 2 µg of anti-Bax 6A7 (Sigma# 
B8429) or anti-Bak Ab-1 (Calbiochem# AM03) antibodies and 20 µL of anti-Mouse IgG-
Agarose beads and incubated overnight at 4°C with rotation.  The beads were pelleted 
and washed three times in CHAPS lysis buffer before being subjected to western blot 
analysis with rabbit anti-Bax (N-20, #sc-493) and rabbit anti-Bak (G-23, #sc-832), 
respectively (Santa Cruz). 
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RNA Interference 
 Small interfering RNA (siRNA) for Mcl-1 (#sc-35877), Bcl-xL (#43630), and 
Control-A (#sc-37007) was purchased from Santa Cruz; Signalsilence siRNA for Atg5 
(#6345), Beclin-1 (#6222) and Control (#6568) were purchased from Cell Signaling.  
Cells were transfected with RNAiMax (Invitrogen) with a reverse transfection protocol 
according to the manufacturer’s protocol.  Briefly, siRNA and RNAiMax were incubated 
in serum-free RPMI 1640 for at least 20 minutes at room temperature.  After siRNA: 
RNAiMax complexes were allowed to form, diluted cells in full serum media (RPMI 1640 
+ 10% FBS) were added and the mixture plated out.  
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CHAPTER THREE: GAMMA-SECRETASE INHIBITION ATTENUATES 
OXALIPLATIN-INDUCED APOPTOSIS THROUGH INCREASED MCL-1 AND/OR 
BCL-XL IN HUMAN COLON CANCER CELLS 
Note to Reader 
 These results have been previously published (Timme et al., 2013) and are 
utilized with permission of the publisher. 
 
Abstract 
The Notch signaling pathway plays a significant role in differentiation, 
proliferation, apoptosis, and stem cell processes.  It is essential for maintenance of the 
normal colon crypt and has been implicated in colorectal cancer oncogenesis.  
Downregulation of the Notch pathway through gamma-secretase inhibitors (GSIs) has 
been shown to induce apoptosis and enhance response to chemotherapy in a variety of 
malignancies.  In this study, we analyzed the effect of MRK-003 (Merck), a potent 
inhibitor of gamma-secretase, on oxaliplatin-induced apoptosis in colon cancer.  
Unexpectedly, gamma-secretase inhibition reduced oxaliplatin-induced apoptosis while 
GSI treatment alone was shown to have no effect on growth or apoptosis.  We 
determined that the underlying mechanism of action involved an increase in protein 
levels of the anti-apoptotic Bcl-2 family members Mcl-1 and/or Bcl-xL, which resulted in 
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reduced Bax and Bak activation.  Blocking of Mcl-1 and/or Bcl-xL through siRNA or the 
small molecule inhibitor obatoclax restored the apoptotic potential of cells treated with 
both oxaliplatin and MRK-003.  Moreover, obatoclax synergized with MRK-003 alone to 
induce apoptosis.  Our findings warrant caution when treating colon cancer with the 
combination of GSIs and chemotherapy, whereas other drug combinations, such as 
GSIs plus obatoclax, should be explored. 
 
Results 
Gamma-Secretase Inhibitors Attenuate Chemotherapy-induced Apoptosis of Colon 
Cancer Cells 
Inhibition of gamma-secretase has shown antitumor effects in a variety of 
cancers in vitro and is thus considered an attractive pharmacological target.  Pre-clinical 
reports using cancer cell lines, patient samples in vitro, and in vivo mouse models on 
the activity of MRK-003, a potent and selective GSI, have reported Notch pathway 
inhibition and antitumor activity in multiple myeloma (Ramakrishnan et al. 2012), Non-
Hodgkin’s leukemia (Ramakrishnan et al. 2012), T-cell acute lymphoblastic leukemia 
(Lewis et al. 2007), breast cancer (Grudzien et al. 2010), pancreatic cancer (Plentz et 
al. 2009; Vo et al. 2011), lung cancer (Konishi et al. 2007), and glioblastoma (Chen et 
al. 2010). 
Oxaliplatin is the first line of chemotherapy for colon cancer.  We hypothesized 
that combining oxaliplatin with gamma-secretase inhibitors would enhance 
chemosensitivity in colon cancer cell lines, as others have shown using alternative 
gamma-secretase inhibitors (Akiyoshi et al. 2008; Aleksic et al. 2008; Meng et al. 2009).   
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Figure 8: Gamma-secretase Inhibition Attenuates Oxaliplatin-induced Apoptosis 
HCT-116 and SW480 cells were treated with 15 µM (HCT-116) or 30µM (SW480) 
oxaliplatin (Oxa) for 48 hours in the absence or presence of 10 µM (HCT-116) or 5 µM 
(SW480) MRK-003 (GSI).  Apoptosis rates were measure by flow cytometry following 
Annexin-V/7-AAD staining (A) and active caspase-3 labeling (B).  (C) Apoptosis rates 
were measured by flow cytometry following active caspase-3 reactivity.  Represented 
data are mean +/- SEM of three independent experiments. 
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To explore the role of gamma-secretase inhibition on oxaliplatin-induced 
apoptosis, two colon cancer cell lines – HCT-116 and SW480 – were treated with 
oxaliplatin in the absence or presence of MRK-003 (Merck, Inc), a potent gamma-
secretase inhibitor.  The doses of MRK-003 used (10 µM for HCT-116 and 5 µM for 
SW480) were determined, after dose response experiments, to be the maximum 
dosage with no quantifiable toxicity (data not shown).  Apoptosis was measured by flow 
cytometry using either Annexin-V with 7-AAD double staining or measuring active 
caspase-3.  Annexin-V binds to the membrane phospholipid phosphatidylserine (PS) 
upon exposure to the external cellular environment in apoptotic cells while 7-AAD is a 
vital dye that is excluded from cells with an intact plasma membrane. The combination 
of oxaliplatin and MRK-003 resulted in a reduction in apoptosis by at least 50% as 
measured by either Annexin-V & 7-AAD positivity (Figure 8a) or activated caspase-3 
(Figure 8b) in both cell lines compared to oxaliplatin alone. 
To confirm that the results were likely due to gamma-secretase inhibition and not 
an off target effect of MRK-003, the effect of alternative gamma-secretase inhibitors on 
apoptosis of oxaliplatin treated cells were repeated using DAPT, GSI-XII, and GSI-XX 
(DBZ), widely used and commercially available GSIs that are structurally distinct from 
MRK-003.  Both cell lines treated with DAPT and GSI-XX showed apoptosis rates 
approximately half that of oxaliplatin-treated cells (Figure 9a,c).  The gamma-secretase 
inhibitor GSI-XII showed a slight decrease in oxaliplatin-induced apoptosis in SW480 
but a slight induction was observed in HCT-116 (Figure 9b).  MRK-003, DAPT, GSI-XII, 
or GSI-XX alone did not induce apoptosis in either HCT-116 or SW480. 
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Figure 9: Effects of Alternative GSIs on HCT-116 and SW480 Colon Cancer Cell 
Lines 
HCT-116 and SW480 cells were treated with 15 µM (HCT-116) or 30µM (SW480) 
oxaliplatin (Oxa) for 48 hours in the absence or presence of 25 µM DAPT (A), 5 µM 
(HCT-116) or 10 µM (SW480) GSI-XII (B), or 2 µM GSI-XX (C).  Apoptosis rates were 
measured by flow cytometry following active caspase-3 reactivity.  Represented data 
are mean +/- SEM of two independent experiments. 
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We further tested the effect of MRK-003 on oxaliplatin-induced apoptosis in three 
additional colon cancer cell lines to determine whether the reduction in apoptosis was 
cell line specific.  We found greater than 50% reduction of apoptosis in oxaliplatin-
treated HT-29, HCT-15, and Colo205 cells in the presence of MRK-003 (Figure 10). 
 
 
Figure 10: Effects of MRK-003 on Oxaliplatin-Induced Apoptosis in HT-29, HCT-15, 
and Colo205 Colon Cancer Cell Lines 
HT-29, HCT-15, and Colo205 were treated with either 30 (HCT-15) or 50 µM (HT-29 
and Colo205) Oxa in the absence or presence of 5 µM (HT-29) or 10 µM MRK-003 
(HCT-15 and Colo205) for 48 hours.  Apoptosis rates were measured by flow cytometry 
following active caspase-3 reactivity.  Represented data are mean +/- SEM of at least 
two independent experiments 
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Figure 11: Gamma-secretase Inhibition Attenuates Irinotecan- and Etoposide-
induced Apoptosis 
HCT-116 and SW480 cells were treated with either 50 µM Etoposide or 50 µM 
Irinotecan in the absence or presence of 10 µM (HCT-116) or 5 µM (SW480) MRK-003 
for 48 hours.  Apoptosis rates were measured by flow cytometry following active 
caspase-3 reactivity.  Represented data are mean +/- SEM of two independent 
experiments. 
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To test if the attenuation of apoptosis was specific to oxaliplatin, we assessed the 
effects of gamma-secretase inhibition with either irinotecan or etoposide.  Again, we 
observed a reduction of apoptosis in HCT-116 with MRK-003 in combination with either 
irinotecan or etoposide; no difference in apoptosis was observed in SW480 (Figure 11).  
Taken together, these data suggest that gamma-secretase inhibition attenuates 
apoptosis induced by chemotherapeutic agents in colon cancer. 
 
The Combined Use of Oxaliplatin and MRK-003 Increases Long-Term Survival in vitro 
We hypothesized the attenuation of apoptosis seen in cells treated with 
oxaliplatin and MRK-003 might be due to increased survival, as measured by MTT 
assay and cell cycle analysis.  HCT-116 and SW480 were treated for 48 hours with 
oxaliplatin with or without MRK-003 and survival was measured by MTT assay.  As 
expected, oxaliplatin treatment decreased viability by approximately 60% for both cell 
lines; the combination of oxaliplatin and MRK-003 showed no difference compared to 
oxaliplatin alone (Figure 12a).  MRK-003 alone had no effect on viability compared to 
vehicle in either cell line. 
Cell cycle analysis showed oxaliplatin induced a G2-M arrest in HCT-116 that 
remained unchanged with the addition of MRK-003; the percentage of cells in G0/G1, 
however, increased (21% to 32%, respectively) (Figure 12b).  Oxaliplatin arrested 
SW480 cells in S phase and no change was observed with the addition of MRK-003 in 
the cell cycle profile (Figure 12b).  MRK-003 alone increased the G0/G1 fraction from 
34% to 48% in HCT-116.  
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Figure 12: Oxaliplatin and MRK-003 Does Not Affect Short-Term Survival 
HCT-116 and SW480 cells were treated with 15 µM (HCT-116) or 30µM (SW480) Oxa 
for 48 hours in the absence or presence of 10 µM (HCT-116) or 5 µM (SW480) MRK-
003.  After treatment, MTT for viability (A) or cell cycle analysis (B) was performed.  
Represented data are mean +/- SEM of three independent experiments. 
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Colony forming assays are a measure of long-term survival.  Cell death may be 
mediated through non-apoptotic mechanisms or may be delayed.  The combination of 
oxaliplatin and MRK-003 remarkably enhanced colony formation in both HCT-116 and 
SW480 when compared to oxaliplatin-treated alone (Figure 13).  Collectively, the data 
suggests that GSI enhances the survival of cells treated with oxaliplatin. 
 
 
Figure 13: Oxaliplatin and MRK-003 Does Not Affect Short-Term Survival 
HCT-116 and SW480 cells were treated with 15 µM (HCT-116) or 30µM (SW480) Oxa 
for 48 hours in the absence or presence of 10 µM (HCT-116) or 5 µM (SW480) MRK-
003.  After treatment, MTT for viability (A) or cell cycle analysis (B) was performed.  
Represented data are mean +/- SEM of three independent experiments. 
 Attenuation of the Apoptotic Signaling Cascade 
The mechanisms underlying gamma-secretase inhibition on oxaliplatin-induced 
apoptosis was examined by evaluating changes in the classical apoptotic signaling 
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cascade.  Cells treated with oxaliplatin and MRK-003 blocked cleavage of PARP (Figure 
14) and caspase-3 (Figure 8) in both HCT116 and SW480 as measured by western blot 
and flow cytometry, respectively.  Caspase activity can be blocked through direct 
interaction with the inhibitor of apoptosis protein (IAP) family members c-IAP1, c-IAP2 
and XIAP, but no differences in protein levels were detected by western blot (data not 
shown).  Second, oxaliplatin-induced cytochrome c release in both HCT-116 and 
SW480 was blocked by the addition of MRK-003 (Figure 15). 
 
 
 
Figure 14: The Combination of Oxaliplatin and MRK-003 Reduces PARP Cleavage 
HCT-116 and SW480 cells were treated with 15 µM (HCT-116) or 30µM (SW480) for 48 
hours in the absence or presence of 10 µM (HCT-116) or 5 µM (SW480) MRK-003.  
Full-length (110 kDa) and cleaved (80 kDa) PARP was analyzed by western blotting of 
whole cell lysates.  Equal protein loading was shown by probing for beta-actin. 
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Figure 15: The Combination of Oxaliplatin and MRK-003 Reduces Cytochrome c 
Release 
HCT-116 and SW480 cells were treated with 15 µM (HCT-116) or 30µM (SW480) for 48 
hours in the absence or presence of 10 µM (HCT-116) or 5 µM (SW480) MRK-003.  
Release of cytochrome c into cytosolic fraction was analyzed by western blot.  Potential 
mitochondrial contamination was detected by COX-IV (positive control lane is a whole 
cell extract).  Beta-actin was used as a loading control. 
Bax and Bak are the two key pro-apoptotic proteins that regulate cytochrome c 
release.  Bax and Bak are activated by conformational changes to promote homo-
oligomerization to create pore-like channels responsible for cytochrome c release 
(reviewed in (Tait et al. 2010)).  The activation of Bax and Bak can be assessed using 
conformation specific antibodies (6A7 for Bax and Ab-1 for Bak) (Hsu et al. 1998).  To 
determine if MRK-003 altered the activation of Bax and Bak in oxaliplatin-treated cells, 
Bax and Bak were immunoprecipitated with their active conformation specific antibodies 
and western blotted.  In response to oxaliplatin, both HCT-116 and SW480 show 
activation of Bax and Bak, which was markedly inhibited in the presence of MRK-003 
(Figure 16). 
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Figure 16: The Combination of Oxaliplatin and MRK-003 Reduces Bax and Bak 
Activation 
HCT-116 and SW480 cells were treated with 15 µM (HCT-116) or 30µM (SW480) for 48 
hours in the absence or presence of 10 µM (HCT-116) or 5 µM (SW480) MRK-003.  
Immunoprecipitation of active Bax and Bak.  Whole cell extracts were probed for total 
Bax, total Bak, and beta-actin. 
Mcl-1 and Bcl-xL levels are Elevated in Oxaliplatin + GSI treated Cells 
The activation of Bax and Bak can be prevented by the anti-apoptotic Bcl-2 
family member proteins Bcl-2, Bcl-xL, Mcl-1, Bcl-w, and A1 (Brunelle et al. 2009).  
Gamma-secretase inhibition has been shown to regulate protein expression of the Bcl-2 
family members (Wang et al. 2010; Ramakrishnan et al. 2012).  We tested whether or 
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not GSI treatment altered total protein levels of Mcl-1 or Bcl-xL (neither cell line 
expressed detectable levels of Bcl-2, data not shown).  Cells treated with MRK-003 
alone increased Mcl-1 protein levels without seemingly affecting Bcl-xL levels in both 
HCT-116 and SW480 (Figure 17).  The combination of oxaliplatin and MRK-003 lead to 
enhanced protein levels of both Mcl-1 and Bcl-xL as compared to oxaliplatin alone in 
both cell lines. 
 
 
Figure 17: MRK-003 Increases Protein Expression of Mcl-1 and Bcl-xL 
HCT-116 and SW480 cells were treated with 15 µM (HCT-116) or 30µM (SW480) for 48 
hours in the absence or presence of 10 µM (HCT-116) or 5 µM (SW480) MRK-003.  
Total levels of Mcl-1 and Bcl-xL were assessed by immunoblotting.  Beta-actin was 
used as a protein loading control. 
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Figure 18: Knockdown of Mcl-1 and/or Bcl-xL Rescues MRK-003 Attenuation of 
Oxaliplatin-induced Apoptosis 
(A) HCT-116 was transfected with increasing amounts of Mcl-1 siRNA as indicated for 
24 hours.  Cells were then treated with 15 µM Oxa in the absence or presence of 10 µM 
MRK-003 for 48 hours.  Apoptosis rates were measure by flow cytometry following 
active caspase-3 reactivity.  Represented data are mean +/- SEM of two independent 
experiments.  (B) Western blot shows efficiency of Mcl-1 knockdown. 
Knockdown or Pharmacologic Inhibition of Mcl-1 and/or Bcl-xL Restores Apoptosis in 
Cells Treated with Oxaliplatin and MRK-003 
To examine whether the MRK-003 induced increase in the anti-apoptotic proteins 
Mcl-1 and/or Bcl-xL is responsible for decreased sensitivity to oxaliplatin treatment, we 
used RNAi interference (siRNA) assays to silence Mcl-1 and/or Bcl-xL.   
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Figure 19: Knockdown of Bcl-xL Rescues MRK-003 Attenuation of Oxaliplatin-
induced Apoptosis 
(A) HCT-116 was transfected with increasing amounts of Bcl-xL siRNA as indicated for 
24 hours.  Cells were then treated with 15 µM Oxa in the absence or presence of 10 µM 
MRK-003 for 48 hours.  Apoptosis rates were measure by flow cytometry following 
active caspase-3 reactivity.  Represented data are mean +/- SEM of two independent 
experiments.  (B) Western blot shows efficiency of Bcl-xL knockdown. 
A dose-dependent knockdown of Mcl-1 resulted in a dose-dependent increase in 
apoptosis in HCT-116 cells treated with oxaliplatin and MRK-003 but had no effect with 
MRK-003 alone as measured by flow cytometry for active caspase-3 (Figure 18a).  
Reduction of Bcl-xL levels in HCT-116 produced a similar dose-dependent increase in 
apoptosis in cells treated with both oxaliplatin and MRK-003 (Figure 19Figure 18a).   
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Figure 20: Simultaneous Knockdown of Mcl-1 and Bcl-xL Rescues MRK-003 
Attenuation of Oxaliplatin-induced Apoptosis 
(A) HCT-116 was transfected with 250 pM Mcl-1 and 25 pM Bcl-xL siRNA as indicated 
for 24 hours.  Cells were then treated with 15 µM Oxa in the absence or presence of 10 
µM MRK-003 for 48 hours.  Apoptosis rates were measure by flow cytometry following 
active caspase-3 reactivity.  Represented data are mean +/- SEM of two independent 
experiments.  (B) Western blot shows efficiency of Mcl-1 and Bcl-xL knockdown. 
As expected, reducing levels of Mcl-1 or Bcl-xL lead to increased sensitivity to 
oxaliplatin.  Knockdown of Mcl-1 and Bcl-xL levels were confirmed by western blot 
(Figure 18b, Figure 19b).  Reducing the levels of both Bcl-xL and Mcl-1 with low 
  43 
picomolar doses greatly increased oxaliplatin-induced apoptosis, which was not 
inhibited with the addition of MRK-003 (Figure 20a).  Simultaneous knockdown of Mcl-1 
and Bcl-xL levels were confirmed by western blot (Figure 20b) 
 
  
Figure 21: Obatoclax Rescues MRK-003 Attenuation of Oxaliplatin-Induced 
Apoptosis. 
HCT-116 was treated with 15 µM Oxa in the absence or presence of 10 µM MRK-003 
and/or 75 nM obatoclax (Obx) for 48 hours.  SW480 was treated with 30 µM Oxa in the 
absence or presence of 5 µM MRK-003 and/or 25 nM obatoclax for 48 hours.  
Apoptosis rates were measured by flow cytometry following active caspase-3 reactivity.  
Represented data are mean +/- SEM of at least two independent experiments. 
To further confirm the role of Mcl-1 and Bcl-xL in mediating the abrogation of oxaliplatin-
induced apoptosis by MRK-003, we used the BH3-peptide mimetic obatoclax (GX15-
070) to broadly antagonize Bcl-2 pro-survival family members Mcl-1 and Bcl-xL.  
Apoptosis inhibition associated with the combination of oxaliplatin and MRK-003 
treatment was reversed with the addition of obatoclax in both HCT-116 and SW480 
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(Figure 21).  Of note, the combination of MRK-003 and obatoclax also resulted in an 
increase in apoptosis in HCT-116 (Figure 21).  Thus, inhibiting Mcl-1 and/or Bcl-xL 
through RNA interference or small molecule inhibitor (obatoclax) lead to a restoration of 
apoptosis in colon cancer. 
 
Discussion 
In this study, we report that the combination of the gamma-secretase inhibitor 
MRK-003 with oxaliplatin elicited potent chemoresistance in colon cancer cells by 
greatly decreasing apoptosis and leading to increased long-term survival.  We showed 
the combination of oxaliplatin and MRK-003 reduced apoptosis in HCT-116, SW480, 
HCT-15, HT-29, and Colo205 colon cancer cell lines by at least half.  The reduction in 
apoptosis could be replicated using alternative GSIs (DAPT and GSI-XX) in HCT-116 
and SW480.  GSI-XII, a fourth GSI used in this study, slightly increased apoptosis by 
10% in HCT-116 and only decreased apoptosis by approximately 7% in SW480.  None 
of the four GSIs used in this study elicited apoptosis by themselves.  When MRK-003 
was combined with other chemotherapeutic agents (etoposide and irinotecan), 
decreased apoptosis was also seen in HCT-116.  MRK-003, however, had no effect on 
apoptosis of etoposide- or irinotecan-treated SW480 cells, a finding reported elsewhere 
using DAPT in combination with various chemotherapeutic agents (Akiyoshi et al. 
2008).  These data suggest that the effects seen are not cell-context specific, mediated 
by gamma-secretase inhibition (not an off-target effect), and not unique to oxaliplatin 
treatment. We observed no change in viability in oxaliplatin-treated cells with or without 
MRK-003 in either HCT-116 or SW480.  Cell cycle analysis showed a slight increase in 
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G0/G1 arrest with the addition of MRK-003 in oxaliplatin-treated HCT-116 cells alone (no 
change was observed in SW480).  These data do not account for the reduction in 
apoptosis seen with MRK-003 treatment.  However, to further support the decrease in 
apoptosis observed in oxaliplatin and MRK-003 treated cell, long-term survival assays 
showed increased cell survival in combination treatment compared to oxaliplatin alone. 
We identified increased protein levels of the anti-apoptotic Bcl-2 family members 
Mcl-1 and Bcl-xL in response to MRK-003 as pivotal players responsible for decreased 
oxaliplatin-induced apoptosis, leading to a reduction of Bax and Bak activation and 
downstream suppression of the apoptotic cascade (cytochrome c release, caspase-3 
cleavage, and PARP cleavage).  Restoration of apoptosis was achieved by blocking 
Mcl-1 and/or Bcl-xL through RNA interference or the Mcl-1/Bcl-xL/Bcl-2 antagonist 
obatoclax.  Knockdown of Mcl-1 and/or Bcl-xL, however, did not induce apoptosis upon 
GSI treatment alone but the combination of GSI and obatoclax did in HCT-116.  From 
these data, we conclude that increased protein levels of Mcl-1 and/or Bcl-xL are 
responsible for the attenuation of oxaliplatin-induced apoptosis observed upon MRK-
003 treatment. 
Several studies have highlighted the role of Notch signaling in the regulation of 
Mcl-1 and Bcl-xL.  Mcl-1 levels are decreased by blocking the Notch pathway via a GSI 
(Wang et al. 2010) or with small-interfering RNA (Zhao et al. 2010) and increased by 
overexpression of NICD (Wang et al. 2010).  GSIs have been shown to increase Noxa, 
a pro-survival BH3-only protein that promotes Mcl-1 degradation (Nefedova et al. 2008; 
Seveno et al. 2012).  Likewise, blocking Notch signaling can decrease Bcl-xL levels 
(Nefedova et al. 2008; Vo et al. 2011).  In contrast, our data shows increased protein 
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levels of Mcl-1 and Bcl-xL upon GSI treatment.  This phenomena has been replicated 
by Liu et. al in T-ALL cell lines when examining the effect of gamma-secretase inhibition 
on chemosensitivity.  One subset of cells exhibited enhancement of apoptosis while 
another subset showed resistance via upregulation of Bcl-xL (Liu et al. 2009).  The 
mechanism by which this occurs is still not well defined. 
Our data also conflicts with other reports in the literature showing synergism 
between cytotoxic agents and GSIs in colon cancer cell lines.  One study showed that 
blocking Notch-1 signaling using GSI34 (a novel gamma-secretase inhibitor) lead to an 
enhancement of oxaliplatin sensitivity (Meng et al. 2009).  Alternatively, DAPT 
sensitized colon cancer cell lines SW480 and DLD-1 to paclitaxel only but not 5-FU, 
camptothecin, TRAIL, or cisplatin (Akiyoshi et al. 2008).  A third group tested the effects 
of GSI-XX (DBZ), another GSI, in combination with platinum compounds (cisplatin, 
carboplatin, and oxaliplatin) on a panel of 20 human colon cancer cell lines (Aleksic et 
al. 2008).  GSI-XX alone had no effect on cell survival and, in combination with cisplatin, 
only a subset exhibited some degree of increased cell death; a few cell lines sensitive to 
the combination of cisplatin and GSI-XX showed no effect with oxaliplatin or carboplatin.  
In our hands, gamma-secretase inhibition using MRK-003, DAPT, or GSI-XX abrogated 
oxaliplatin-induced apoptosis via increased Mcl-1 and/or Bcl-xL protein levels, as seen 
by Liu et al. (Liu et al. 2009).  The pleotropic nature of gamma-secretase inhibition on 
chemotherapy-induced apoptosis is not well understood.  It likely could be a reflection of 
complex context-dependent signaling downstream of the Notch pathway, and thus may 
only be of clinical utility to a particular (as yet undefined) subtype of colorectal cancer. 
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The observed effects of MRK-003, DAPT, and GSI-XX on attenuating 
chemotherapy-induced apoptosis may not be caused by Notch inhibition but rather 
differential targeting of other known gamma-secretase substrates.  Gamma-secretase 
primarily catalyzes the intramembranous cleavage of Notch and APP (amyloid 
precursor protein).  However, it has also been shown to target at least a dozen known 
type I transmembrane proteins, including E-cadherin, ErbB4, CD44, and c-Met, but their 
mechanism and function is not well studied (for review, see (Haapasalo et al. 2011)).  
Also, the specificity of GSIs for different substrates may drive the discrepancies found in 
the literature, thus it will be important to understand the biochemical differences 
between specific GSIs, particularly since we showed that GSI-XII did not have the same 
effect as the other three GSIs.  While we used four commercially available inhibitors 
known to block both Notch cleavage and activity as well as induce apoptosis in multiple 
tumor cell lines, we cannot rule out the possibility that these GSIs may also indirectly 
target other molecular pathways, such as pro-apoptotic signaling pathways, which may 
outweigh or antagonize any pro-apoptotic effects conferred by reduced Notch signaling 
in colon cancer cells.  Therefore, the contribution of single, combinatorial, or complete 
ablation of all four Notch receptors on chemosensitivity is needed to address these 
concerns.  The newly emerging neutralizing antibodies to individual Notch receptors will 
surely help to answer this question. 
 Standard chemotherapy approaches may need to be modified to include other 
novel inhibitors.  Despite the apparent discrepancies of gamma-secretase inhibition on 
chemosensitivity, we were able to restore the attenuation of oxaliplatin-induced 
apoptosis seen with MRK-003 by antagonizing Mcl-1 and/or Bcl-xL.  Combining GSIs 
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and chemotherapy with an anti-apoptotic Bcl-2 family member agonist like obatoclax 
may be a valid therapeutic approach.  We also found enhanced apoptosis with MRK-
003 and obatoclax combined.  Previous studies have shown sensitization with the 
combination of GSIs and the BH3 mimetic ABT-737 (antagonizes Bcl-2/Bcl-xL/Bcl-w but 
not Mcl-1 (Oltersdorf et al. 2005)) in GSI-sensitive cell lines where GSI alone increased 
Noxa levels, leading to subsequent Mcl-1 degradation (Li et al. 2010; Seveno et al. 
2012).  Our data shows MRK-003 synergism with obatoclax in GSI-resistant colon 
cancer cell lines where GSI alone increases Mcl-1 and Bcl-xL levels.  Therefore, 
combining GSIs with other targeted therapeutics instead of chemotherapy may be a 
more effective strategy in the treatment of colorectal cancer. 
 To our knowledge, the only published Phase II clinical trial studying the efficacy 
of gamma-secretase inhibitor – RO4929097 – monotherapy in metastatic colorectal 
cancer patients demonstrated no antitumor effects (Strosberg et al. 2012).  
Nevertheless, there are multiple clinical trials investigating mono- and combination 
therapies involving GSIs in a wide variety of tumors (www.clinicaltrials.gov).  The results 
posed here do not diminish the potential use of GSIs in a clinical setting but rather 
suggest caution when developing drug combinations.  First, further detailed mechanistic 
studies looking at the biochemical differences in substrate specificity and potential off-
target effects of the many available GSIs are needed.  Also, the effects of gamma-
secretase inhibition in relation to cell context and interactions with signaling pathways 
needs further clarification as there are clear indications that GSIs can have opposing 
effects even in same tumor types.  Third, the potential still exists for using GSIs in 
combination with other therapeutic agents to elicit anti-tumorigenic responses.  Our 
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results provide a cautionary tale for broad application of gamma-secretase inhibitors.  
Understanding the actions of this drug when used in combination with standard 
chemotherapy and/or targeted therapies will provide greater knowledge of its potential 
use for a personalized approach to cancer treatment. 
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CHAPTER FOUR: TARGETING AUTOPHAGY-SENSITIZED COLON CANCER 
CELLS TO GAMMA-SECRETASE INHIBITORS 
Abstract 
Gamma-secretase has been considered an attractive target for colorectal cancer 
due to its ability to block Notch signaling.  In the previous section, we found that 
gamma-secretase inhibitors (GSIs) alone had no effect on cell proliferation or apoptosis 
in human colorectal cancer cell lines.  When GSIs were combined with chemotherapy, 
apoptosis was abrogated and long-term survival increased.  The combination of 
oxaliplatin, the first line of chemotherapy for colorectal cancers, with MRK-003, a 
specific GSI, resulted in elevated levels of anti-apoptotic Bcl-2 family members Mcl-1 
and Bcl-xL.  Addition of the Bcl-2 inhibitor obatoclax (Obx) and knockdown of Mcl-1 
and/or Bcl-xL were able to, at least partially, restore apoptosis.  Interestingly, the 
combination of MRK-003 and obatoclax induced cell death. 
 We show here that cell death due to the combination of MRK-003 and obatoclax 
was only partially due to apoptosis in HCT-116 and SW480 by measuring Annexin-V 
positivity, Parp-1 cleavage, caspase-3 cleavage, and effects on death using the pan-
caspase inhibitor z-VAD-fmk.  Obatoclax has been shown to induce autophagy, a 
cannibalistic cell survival pathway activated upon cellular stress.  We examined if 
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autophagy played a role in increasing cell death due to the MRK-003 + Obx 
combination. 
 We measured autophagic flux, the complete process of autophagy initiation and 
progression leading to the release of degraded substrates, by the bafilomycin A1 clamp 
assay and total p62 levels.  The bafilomycin A1 clamp assay prevents LC3-II 
degradation, a protein that is generated during autophagic flux initiation and degraded 
upon completion; p62 is a degraded during autophagic flux.  Our data indicates that 
autophagy is blocked with the combination of MRK-003 and obatoclax.  We saw no or 
little decrease in LC3-II levels with the bafilomycin clamp assay and increased total p62 
levels.  Our data also indicated that each drug alone induced autophagy.  What remains 
unclear is how blockage of autophagy is attained with two drugs that individually induce 
autophagy. 
We are the first to show that gamma-secretase inhibitors stimulate cytoprotective 
autophagy; this may be a reason for their insensitivity in our human colon cancer cell 
lines.  To address whether modulation of autophagy can sensitize GSI-treated colon 
cancer cells, we blocked autophagy by the autophagy inhibitors 3-MA and bafilomycin 
A1 and by knockdown of the critical autophagy genes Beclin-1 or Atg5.  Blocking 
autophagy with bafilomycin A1 and knockdown with both Beclin-1 and Atg5 increased 
cell death in GSI-treated cells.  The mechanism that stimulates autophagy is GSI-
treated cells remains unknown. 
These findings suggest that one possible explanation for the insensitivity of colon 
cancer cell lines to GSI treatment is the induction of cytoprotective autophagy.  This 
calls into question the validity of using GSIs to treat colon cancer patients 
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Results 
Apoptosis is Partially Responsible for Cell Death Induced by the Combination of MRK-
003 and Obatoclax  
In the previous chapter, we observed high levels of cell death under the 
microscope in HCT-116 and SW480 cells when treated with both MRK-003 and 
obatoclax compared to either drug alone.  However, only 12% and 4% of HCT-116 or 
SW480 cells, respectively, were positive for active caspase-3 (Figure 8b).  To further 
characterize the role of apoptosis in the observable cell death, HCT-116 and SW480 
were treated with both drugs and apoptosis was assessed 48- hours post treatment by 
Annexin-V & 7-AAD staining.  HCT-116 cells showed similar levels of early apoptosis 
[Annexin-V (+) / 7-AAD (-)] and late apoptotic / dead [Annexin-V (+) / 7-AAD (+)] cells in 
MRK-003 + Obx treated cells (Figure 22a).  SW480, however, had almost no early 
apoptotic positive cells; most labeled positive for late apoptosis / dead (Figure 22b).  
Similarly, higher Parp-1 cleavage, a marker of apoptosis, was observed in HCT-116 by 
western blot in MRK-003 + Obx treated cells as early as 24 hours but no detectable 
levels of Parp-1 cleavage was observed in SW480 by 48 hours (Figure 25a-b).  Cell 
death also assessed using the vital dye propidium iodide (PI), which is excluded from 
live cells, resulted in similar levels of cell death when compared to the Annexin-V & 7-
AAD assay in both HCT-116 and SW480 (Figure 23).  Cell death will henceforth be 
assessed by PI staining for all following experiments. 
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Figure 22: Contribution of Apoptosis in Cell Death Mediated by the Combination 
of MRK-003 and Obatoclax 
HCT-116 (A) and SW480 (B) cells were treated with 10 µM (HCT-116) or 5µM (SW480) 
MRK-003 (GSI) in the absence or presence of 75 nM (HCT-116) or 25 nM (SW480) 
obatoclax (Obx) for 48 hrs.  Apoptosis rates were measure by flow cytometry following 
Annexin-V/7-AAD staining.  Represented data are mean +/- SD of two independent 
experiments. 
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Figure 23: The Combination of MRK-003 and Obatoclax Induces Cell Death in 
Human Colon Cancer Cell Lines 
HCT-116 (A) and SW480 (B) cells were treated with 10 µM (HCT-116) or 5µM (SW480) 
MRK-003 (GSI) in the absence or presence of 75 nM (HCT-116) or 25 nM (SW480) 
obatoclax (Obx) for 48 hrs.  Cell death rates were measure by flow cytometry following 
PI staining.  Represented data are mean +/- SD of two independent experiments. 
 The classical markers of apoptosis, viable Annexin-V positivity, caspase-3 
cleavage, and Parp-1 cleavage, were present in HCT-116 but not SW480.  To 
determine if apoptosis is the only mechanism responsible for the observed cell death, 
HCT-116 and SW480 were treated with MRK-003 and Obx in the presence or absence 
of the pan caspase inhibitor z-VAD-fmk.  Oxaliplatin-treated cells were used as a 
positive control to show greater than 50% suppression of cell death in the presence of 
z-VAD-fmk.  The addition of z-VAD-fmk to MRK-003 + Obx-treated cells suppressed cell 
death by 50% in HCT-116 and 20% in SW480 (Figure 24).  Interestingly, z-VAD-fmk 
had no effect on cell death on Obx-treated cells in HCT-116.  These data suggest an 
alternative cell death mechanism may be responsible for killing even when apoptosis is 
inhibited. 
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Figure 24: MRK-003 + Obx-induced Cell Death is Partially Inhibited by Z-VAD-FMK 
HCT-116 (A) was treated with 10 µM MRK-003 (GSI) and 75 nM obatoclax (Obx) in the 
presence or absence of 20 µM z-VAD-fmk for 48 hrs.  SW480 (B) was treated with 5 µM 
MRK-003 and 75 nM Obx in the presence or absence of 20 µM z-VAD-fmk for 48 hrs.  
Cells were treated with 50 µM oxaliplatin (Oxa) as a positive control.  Cell death rates 
were measure by flow cytometry following PI staining.  Represented data are mean +/- 
SD of two independent experiments. 
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Figure 25: Total Levels of LC3-II are Increased in MRK-003 + Obx Treated Cells 
HCT-116 (A) and SW480 (B) cells were treated with 10 µM (HCT-116) or 5µM (SW480) 
MRK-003 (GSI) in the absence or presence of 75 nM (HCT-116) or 25 nM (SW480) 
obatoclax (Obx) for 48 hrs.  Total levels of LC3-II and PARP-1 were assessed by 
western blot.  Beta-actin was used as a protein loading control. 
Cytoprotective Autophagy is Blocked in MRK-003 + Obatoclax-Treated Cells 
 In addition to repressing apoptosis, the anti-apoptotic Bcl-2 family proteins can 
also directly bind to Beclin-1, preventing autophagy initiation (Rahmani et al. 2012; Tang 
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et al. 2012; Schwartz-Roberts et al. 2013).  Autophagy, a process of recycling cellular 
material for energy, is thought to act as a survival process during times of stress.  
Therefore, obatoclax may both promote apoptosis and facilitate autophagy 
simultaneously.  Measuring autophagy must be performed using multiple assays as no 
single assay provides conclusive information. 
Total LC3-II protein levels, a specific autophagic marker, was assessed in HCT-
116 and SW480 cells treated with MRK-003 or obatoclax, alone or in combination, by 
western blot.  First, we found slight increases in LC3-II levels in both cell lines with each 
drug alone compared to untreated controls; levels were further elevated in combination 
treatment (Figure 25). 
 
 
Figure 26: Increased Acidic Vesicular Organelles by Acridine Orange Staining in 
MRK-003 + Obx Treated Cells 
HCT-116 and SW480 cells were treated with 10 µM (HCT-116) or 5µM (SW480) MRK-
003 (GSI) in the absence or presence of 75 nM (HCT-116) or 25 nM (SW480) obatoclax 
(Obx) for 48 hrs.  Autophagic vesicles were detected in live cells by acridine orange 
staining and examined by fluorescence microscopy. 
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When autophagosomes fuse with the acidic lysosomes, the resultant 
autolysosome is an acidic compartment.  Acridine Orange (AO) is a dye used to detect 
autophagic vesicles.  Acridine orange is an acidotropic (pH sensitive) dye that crosses 
into lysosomes (and other acidic compartments) within the cell where it becomes 
protonated and trapped within the organelle and then forms aggregates that emit red 
fluorescence; at neutral pH, the unprotonated dye emits green fluorescence.  Detection 
of acidic vesicular organelles (AVOs), a morphologic characteristic of autophagy, by 
acridine orange staining was qualitatively analyzed using an inverted fluorescent 
microscope.  The combination of MRK-003 and obatoclax showed increased staining of 
AVOs as compared to control or either drug alone in HCT-116; no differences could be 
seen in SW480 (Figure 26). 
 
 
Figure 27: Elevated Levels of p62 in MRK-003 + Obx Treated Cells 
HCT-116 (A) and SW480 (B) cells were treated with 10 µM (HCT-116) or 5µM (SW480) 
MRK-003 (GSI) in the absence or presence of 75 nM (HCT-116) or 25 nM (SW480) 
obatoclax (Obx) for 48 hrs.  Total level of p62 was assessed by western blot.  Beta-actin 
was used as a protein loading control. 
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The protein p62 is degraded during autophagy induction and serves as another 
autophagy marker; p62 levels should inversely correlate with LC3-II levels during 
autophagy promotion.  When p62 was measured in treated cells, we found increased 
protein levels in MRK-003 + Obx-treated cells compared to either drug alone (Figure 
27).  The increase in p62 levels do not inversely correlate with LC3-II levels, suggesting 
that autophagy is not being promoted in combined treatment to elicit cell death. 
 To address this inconsistency, we must reevaluate what information total 
LC3-II levels provide.  Elevated LC3-II protein levels can indicate either: 1) increased 
autophagy induction or 2) blockage in autophagy.  LC3-II has a half-life of approximately 
30 minutes.  If autophagy is inhibited by blocking the fusion of the autophagosome to 
the lysosome for a period of time, allowing for accumulation of LC3-II without 
subsequent degradation, we can compare the levels of LC3-II in these cells to their 
unblocked counterpoint to determine whether autophagy is being induced or blocked.  
This feature can be exploited by the bafilomycin A1 clamp assay (Rubinsztein et al. 
2009).  In this assay, cells are treated with the compound of interest and during the last 
four hours of treatment, saturating concentration of bafilomycin A1, a drug that blocks 
the fusion of the autophagosome with the lysosome, is added.  When comparing cells 
treated with bafilomycin A1 to those without, increased levels of LC3-II would indicate 
induction of autophagy while decreased or no change in LC3-II levels would indicate a 
block in autophagy.  When MRK-03 + Obx treated HCT-116 and SW480 cells were 
subjected to the bafilomycin A1 clamp assay, we saw a decrease in LC3-II levels in the 
presence of Baf A1 in HCT-116 (Figure 28a, compare lanes 8 to 4) and no change in 
LC3-II levels in SW480 (Figure 28b, compare lanes 8 to 4).   
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Figure 28: Blocked Autophagic Flux in MRK-003 + Obx Treatment and Increased 
Autophagic Flux in GSI Treatment 
HCT-116 (A) and SW480 (B) cells were treated with 10 µM (HCT-116) or 5µM (SW480) 
MRK-003 (GSI) in the absence or presence of 75 nM (HCT-116) or 25 nM (SW480) 
obatoclax (Obx) for 48 hrs.  During the last four hours, cells were treated with 400 nM 
bafilomycin A1 for 4 hours and harvested.  Total level of LC3-II was assessed by 
western blot.  Beta-actin was used as a protein loading control. 
We see an increase in LC3-II levels in the presence of Baf A1 for each drug alone in 
both HCT-116 (Figure 28a, compare lanes 6 to 2 and lanes 7 to 3) and SW480 (Figure 
28b, compare lanes 6 to 2 and lanes 7 to 3).  These data indicate that both MRK-003 
and obatoclax alone may promote autophagy but when combined, autophagy is 
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somehow blocked.  In summary, we see an absence (with MRK-003 alone) or lower 
levels (with obatoclax alone) of cell death with simultaneous autophagy induction in our 
colon cell lines; increased cell death (with MRK-003 + Obx combined treatment) is 
observed simultaneously with blocked autophagy.  Our findings suggest a 
cytoprotective role for autophagy in this cellular context.  It remains unclear how the 
combination of MRK-003 and obatoclax blocks autophagy when both drugs alone 
promote it. 
 
Blocking Autophagy Sensitizes Colon Cancer Cells to GSI Treatment 
If we instead focus on the data suggesting induction of cytoprotective autophagy 
in insensitive GSI treated colon cancer cells, we can hypothesize that blocking 
autophagy may overcome their resistance.  To test this, we treated colon cells with two 
common compounds used to suppress autophagy – 3-MA and bafilomycin A1 (note: 
neither compound is a specific autophagy inhibitor).  3-MA is a nucleotide derivative that 
blocks class III PI3 kinases and prevents autophagy initiation (Seglen et al. 1982).  
When treated with 3-MA, we did not see sensitization of GSI-treated HCT-116 or 
SW480 cells (Figure 29a-b).  As expected, 3-MA did increased cell death in obatoclax-
treated cells and in GSI + Obx treated HCT-116.  Bafilomycin A1, an ATPase inhibitor, 
blocks fusion of the autophagosome to the lysosome.  When treated with bafilomycin 
A1, we saw massive increases in cell death in GSI-treated HCT-116 (Figure 30).  
Bafilomycin A1 had no effect on cell death in Obx-treated or MRK-003 + Obx-treated 
cells.  
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Figure 29: Blocking Autophagy through 3-MA Does Not Sensitize GSI-treated 
Cells 
HCT-116 (A) was treated with 10 µM MRK-003 (GSI) and 75 nM obatoclax (Obx) in the 
presence or absence of 5 mM 3-MA for 48 hrs.  SW480 (B) was treated with 5 µM MRK-
003 and 75 nM Obx in the presence or absence of 5mM 3-MA for 48 hrs.  Cell death 
rates were measure by flow cytometry following PI staining.  Represented data are 
mean +/- SD of two independent experiments. 
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Figure 30: Blocking Autophagy with Bafilomycin A1 Induces Cell Death in GSI-
treated Cells 
HCT-116 was treated with 10 µM MRK-003 (GSI) and 75 nM obatoclax (Obx) in the 
presence or absence of 10 nM bafilomycin A1 for 48 hrs.  Cell death rates were 
measure by flow cytometry following PI staining.  Represented data are mean +/- SD of 
two independent experiments. 
 To further characterize the cytoprotective role of autophagy mediating GSI 
insensitivity, we knocked down two essential autophagy proteins – Beclin-1 and Atg5 – 
by RNAi techniques.  Beclin-1 is required during the vesicle nucleation step of 
autophagy.  Partial knockdown of Beclin-1 resulted in 40% cell death; treatment with 
MRK-003 increased cell death to ~60% (Figure 31a).  Atg5 is required to convert LC3-I 
to LC3-II during autophagosome formation.  Partial knockdown of Atg5 sensitized cells 
to MRK-003, increasing cell death by ~15% (Figure 31a).  Knockdown was verified by 
western blot (Figure 31b).  These data further support the theory that inhibition of 
autophagy may sensitize colon cells to gamma-secretase inhibitors. 
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Figure 31: Knockdown of Beclin-1 or Atg5 Increases Cell Death in GSI-treated 
Cells 
HCT-116 was transfected with 50 nM siRNA (Control, Beclin-1, or Atg5) for 24 hours 
and then treated with 10 µM MRK-003 (GSI) and 75 nM obatoclax (Obx) 48 hrs.  Cell 
death rates were measure by flow cytometry following PI staining.  Represented data 
are mean +/- SD of two independent experiments. 
Discussion 
 Here, we show that the GSI MRK-003 in combination with obatoclax induces cell 
death in colon cancer cell lines.  Others have shown increased killing with the 
combination of GSI and anti-apoptotic Bcl-2 agonists but we are the first to report a role 
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for autophagy in mediating cell death with combination treatment.  Apoptosis seems to 
only have a partial role in this cell death induction.  HCT-116 exhibited features of 
apoptosis by Annexin-V positivity and Parp-1 cleavage, both absent in SW480.  Neither 
cell line showed significant caspase-3 cleavage.  Inhibition of apoptosis by z-VAD-fmk 
blocked MRK-003 + Obx induced cell death by 50% in HCT-116 and 20% in SW480.  
Therefore, we concluded that apoptosis was not sufficient in mediating cell death 
induced by the combination of MRK-003 and obatoclax. 
Obatoclax also induces autophagy, likely through antagonizing the anti-apoptotic 
Bcl-2 family members Mcl-1 and Bcl-xL, which in addition to blocking apoptosis, can 
also block autophagy via direct binding to Beclin-1 (see above).  We decided to assess 
the modulation of autophagy with this combination to examine its role in mediating the 
cell death observed.  Alone, MRK-003 and obatoclax both promote autophagic flux.  
However, in combination, autophagy is inhibited.  Our data showed no change or 
decreased levels of LC3-II during the bafilomycin clamp assay and increased p62 
protein levels, all indicators of blocked autophagic flux.  The mechanism for this remains 
unknown. 
Only one report has looked at the effect of GSIs on modulation of autophagy in 
mouse embryonic fibroblasts; they found no differences in autophagy (Neely et al. 
2011).  We show are the first to show that the GSI MRK-003 increases autophagic flux 
in both HCT-116 and SW480.  It remains unclear how this occurs as MRK-003 also 
increases protein levels of Mcl-1 and to some extent Bcl-xL, which in theory should 
block autophagy.  Cytoplasmic localization of these proteins may explain this 
inconsistency, as only ER-localized, not mitochondria-localized, anti-apoptotic Bcl-2 
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protein can inhibit autophagy (Pattingre et al. 2005).  Therefore, if Mcl-1 and/or Bcl-xL 
are not translocated to the ER even with increased total protein levels, autophagy will 
not be blocked.  Induction of autophagy in GSI-treated cells may be due to a general 
stress response or due to specific mechanism of action by GSI.  This is an area that 
needs to be further explored. 
 As mentioned, we are the first to show that cytoprotective autophagy may 
contribute to GSI-insensitivity in human colon cancer cell lines.  We targeted autophagy 
via two chemical inhibitors – 3-MA and bafilomycin A1 – or through RNAi to examine its 
role in mediating GSI sensitivity.  We found that bafilomycin A1, but not 3-MA, 
dramatically induced cell death in GSI-treated cells.  Why both compounds did not have 
similar effects is unknown but this phenomenon has been reported in the literature 
(Shingu et al. 2009; Kanematsu et al. 2010).  To address this, other autophagy inhibiting 
compounds, like chloroquine, need to be utilized.  In addition to pharmacologically 
inhibiting autophagy, we knocked down two critical autophagy proteins – Beclin-1 and 
Atg5 – via RNAi.  Knockdown of both Beclin-1 and Atg5 enhanced cell death in GSI-
treated cells by ~20%.  Our data supports a cytoprotective role of autophagy in 
sensitivity to GSIs in human colon cancer cell lines.  Other GSI-insensitive cell types, 
i.e. breast cancer cell lines, need to be examined to determine if autophagy induction by 
GSI is universal.  Therefore, we concluded that targeting autophagy in GSI-insensitive 
human colon cancer cell lines might be a rational approach to render cells sensitive to 
GSI treatment. 
 As mentioned previously, GSIs have yet to show any clinical significance in the 
treatment of colorectal cancer.  We are the first to show that GSI insensitivity is due to 
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cytoprotective autophagy induction, though other mechanisms, like increased anti-
apoptotic Bcl-2 family proteins, may also play a role.  Our data supports the theory of 
targeting autophagy to modulate GSI sensitivity and therefore, combination of GSIs with 
autophagy inhibitors may be clinically useful. 
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CHAPTER 5: CONCLUSION 
 In conclusion, we show two potential drug resistance mechanisms to gamma-
secretase inhibitors when given in combination with chemotherapy or as a single agent 
in colorectal cancer cells.   
In the first scenario, combination of the GSI MRK-003 with oxaliplatin, the first 
line of chemotherapy for colorectal cancer patients, resulted in attenuation of apoptosis 
in the colon cancer cell lines HCT-116, SW480, HT-29, HCT-15, and Colo205.  
Abrogation of chemotherapy-induced apoptosis by GSIs was further supported by using 
alternative GSIs (DAPT and GSI-XX) and by other chemotherapeutic agents (etoposide 
and irinotecan).  Decreased apoptosis seen in the combination of oxaliplatin and MRK-
003 resulted in increased colony formation (long-term survival) compared to oxaliplatin 
treatment alone, refuting the possibility of delayed apoptosis.  A decrease in the entire 
apoptotic cascade, from caspase-3 cleavage, cytochrome c release, and Bax and Bak 
activation, was observed in the combination of oxaliplatin and MRK-003.  We found an 
increase in protein levels of the anti-apoptotic protein Mcl-1 with MRK-003 treatment 
alone and in combination with oxaliplatin compared to control and oxaliplatin-treated 
cells, respectively.  We also observed elevated levels of the anti-apoptotic protein Bcl-
xL with the combination of oxaliplatin and MRK-003 compared to oxaliplatin treatment 
alone.  We knocked-down both proteins, individually and simultaneously, and 
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pharmacologically inhibited them with their agonist obatoclax to show that Mcl-1 and/or 
Bcl-xL played a causative role in the attenuation of oxaliplatin-induced apoptosis by the 
GSI MRK-003. 
In the second scenario, we have shown that the GSI MRK-003 has little to no 
effect on cell death as a single agent in colon cancer cell lines.  However, we did 
observe high levels of cell death in the combination of MRK-003 and obatoclax that was 
only partially (in HCT-116) or not (in SW480) due to apoptosis.  Literature has 
supported a role of the anti-apoptotic proteins Bcl-2, Bcl-xL, and Mcl-1 in preventing 
autophagy through binding and sequestering the autophagy protein Beclin-1.  As 
autophagy is primarily a survival mechanism of the cell during times of stress, degrading 
proteins and cellular material for recycling and energy production, we assessed the 
modulation of autophagy in the combination of MRK-003 and obatoclax.  Both MRK-003 
and obatoclax promoted autophagic flux as single agents but inhibited autophagy in 
combination.  Why two agents that individually promote autophagy block it in 
combination remains unknown.  However, we were intrigued by the fact that the GSI 
MRK-003 induced autophagy and hypothesized that blocking autophagy could sensitize 
colon cells to GSIs.  We blocked autophagy via two chemical inhibitors – 3-MA and 
bafilomycin A1 – and through knockdown of the autophagy proteins Beclin1 and Atg5 to 
show sensitization to MRK-003 in autophagy-deficient colon cancer cell lines. 
The results of this work have important implications for the clinical use of GSIs.  
While this work provides a cautionary tale for the use of GSIs alone or in combination 
with chemotherapy in the treatment of colorectal cancer, the apoptosis inhibition or 
autophagy induction seen may be off-target effects of GSIs and not due to 
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downregulation of Notch signaling.  Newly developed monoclonal Notch receptor 
antibodies will need to be tested in vitro and in vivo to address this issue.  Furthermore, 
because Notch signaling can be both oncogenic and tumor suppressive, we need to 
determine what tumor types will potentially benefit from GSIs.  Multiple ongoing Phase I 
and II clinical trials in both liquid and solid tumors are underway utilizing a variety of 
GSIs (MRK-0752 Merck, RO4929097 Roche, BMS-906024 Bristol-Meyers Squibb, and 
PF-03084014 Pfizer) as single agents or in combination with chemotherapy or other 
targeted drugs to address this issue.  One small Phase II clinical trial using RO4929097 
in refractory metastatic colorectal patients showed no radiographic response; in vitro 
experiments using GSIs in colon cancer cell lines have resulted in conflicting data 
(Strosberg et al. 2012).  It is clear likely that the indicated study dosage and schedule 
are not optimal to achieve measureable responses.  It may also be possible that only 
certain subsets of a tumor type may respond to GSI therapy and therefore biomarkers 
identifying these subtypes will be useful. 
We may instead need to rethink how targeting Notch signaling using GSIs can be 
of clinical utility.  There are conflicting reports of the role of Notch signaling in 
tumorigenesis; evidence exists supporting both oncogenic and tumor suppressive 
functions within tumor types.  On one hand, the Notch pathway has been shown to be 
upregulated in colorectal tumors compared to normal (Reedijk et al. 2008); a different 
group has shown upregulation of the Notch pathway in low-grade adenomas but not 
adenocarcinomas (Fre et al. 2009).  In pancreatic cancer, recent work has also shown 
differential effects of Notch pathway inhibition on precursor lesions (pancreatic 
intraepithelial neoplasia, PanIN) and pancreatic ductal adenocarcinomas (PDAC).  
  71 
Treatment of mice PanIN lesions with GSIs lead to decreased progression whereas 
treatment of PDAC lesions with GSIs had no effect on progression.  Further studies 
have revealed opposite effects of individual Notch receptors on pancreatic cancer 
progression in mice – embryonic deletion of Notch1 produces advanced stage PanIN 
lesions while embryonic deletion of Notch2 inhibits PanIN progression (Avila et al. 
2013).  Therefore, Notch signaling, and each individual receptor, may have differential 
roles in tumor initiation and progression. 
Additionally, drugs targeting developmental pathways like Notch may not work 
like cytotoxic agents to kill cells but rather function to modulate cell fate programs to 
sensitize cells to cytotoxic or growth arrest signals.  Or, their main target might be 
cancer-initiating cells rather than bulk tumor cells.  Significant evidence exists for the 
role of Notch signaling in the maintenance of a variety of tumor-initiating cells in the 
colon (Sikandar et al. 2010), brain (Fan et al. 2006), breast (Wong et al. 2012), and T-
cell leukemia (Armstrong et al. 2009).  Therefore, the main therapeutic target of GSIs 
may be stem-like tumor-initiating cells.  In a recent study using Her2/Neu positive breast 
xenographs in mice, the effect of two GSIs (MRK-003 and LY411,575) alone and in 
combination with Herceptin (trastuzumab) was studied (Pandya et al. 2011).  Herceptin 
treatment alone lead to complete tumor regression; neither GSI had an effect alone or in 
combination with Herceptin on tumor size.  However, approximately 50% of Herceptin-
treated mice showed tumor recurrence; few (using LY411,575) to no (using MRK-003) 
mice treated with the combination of Herceptin and GSI showed tumor recurrence.  
Thus, GSIs may be clinically significant in limiting recurrence more than tumor 
shrinkage. 
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In conclusion, a comprehensive understanding of the role of Notch signaling, 
especially the contribution of individual Notch receptors, in tumor initiation, progression, 
metastasis, and recurrence needs further clarification.  This will help determine whether 
or not GSIs, or more targeted Notch receptor agonists, will be a valid therapeutic 
approach to combating specific tumor subtypes. 
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ORIGINAL PAPER
Gamma-secretase inhibition attenuates oxaliplatin-induced
apoptosis through increased Mcl-1 and/or Bcl-xL in human colon
cancer cells
Cindy R. Timme • Mike Gruidl • Timothy J. Yeatman
! Springer Science+Business Media New York 2013
Abstract The Notch signaling pathway plays a signifi-
cant role in differentiation, proliferation, apoptosis, and
stem cell processes. It is essential for maintenance of the
normal colon crypt and has been implicated in colorectal
cancer oncogenesis. Downregulation of the Notch pathway
through gamma-secretase inhibitors (GSIs) has been shown
to induce apoptosis and enhance response to chemotherapy
in a variety of malignancies. In this study, we analyzed the
effect of MRK-003 (Merck), a potent inhibitor of gamma-
secretase, on oxaliplatin-induced apoptosis in colon cancer.
Unexpectedly, gamma-secretase inhibition reduced oxa-
liplatin-induced apoptosis while GSI treatment alone was
shown to have no effect on growth or apoptosis. We
determined that the underlying mechanism of action
involved an increase in protein levels of the anti-apoptotic
Bcl-2 family members Mcl-1 and/or Bcl-xL which resulted
in reduced Bax and Bak activation. Blocking of Mcl-1 and/
or Bcl-xL through siRNA or the small molecule inhibitor
obatoclax restored the apoptotic potential of cells treated
with both oxaliplatin and MRK-003. Moreover, obatoclax
synergized with MRK-003 alone to induce apoptosis. Our
findings warrant caution when treating colon cancer with
the combination of GSIs and chemotherapy, whereas other
drug combinations, such as GSIs plus obatoclax, should be
explored.
Keywords Gamma-secretase inhibitor ! Oxaliplatin !
Mcl-1 ! Bcl-xL ! Colon
Background
Colorectal cancer accounts for almost 50,000 deaths each
year in the United States and remains the third leading cause
of cancer-related mortality [1]. While surgical resection
remains the gold standard of treatment for localized disease,
chemotherapy combinations with oxaliplatin, irinotecan,
5-fluorouracil, the VEGF inhibitor bevacizumab, and EGFR
inhibitors have led to significant improvements in survival at
all stages [2, 3]. However, most metastatic colorectal cancer
patients eventually develop drug resistance to current ther-
apies so new strategies are needed for treatment and
improved survival of these patients.
The Notch pathway is an evolutionarily conserved path-
way important in cell differentiation, proliferation, apopto-
sis, cell fate decisions, and stem cell renewal during
development and cancer. The Notch family consists of four
trans-membrane receptors (Notch1–4) that are activated
upon binding to their ligands (Jagged 1–2 andDelta-like 1, 3,
and 4) located on adjacent cells, triggering two proteolytic
processing events. The first cleavage by TACE/ADAM
metalloproteases releases the extracellular domain followed
by gamma-secretase mediated cleavage to release the Notch
intracellular domain (NICD) [4]. The activated form of
Notch, NICD, translocates to the nucleus and binds to the
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transcriptional repressorCSL (CBF-1/suppressor of hairless/
Lag-1) and recruitsMAML-1 (mastermind-like-1) and p300/
CBP to induce transcription of Notch target genes such as the
Hes (hairy/enhancer of split) and Hey family members [5],
c-myc, p21, and cyclin D1 (reviewed in [6]).
Aberrant activation of Notch signaling has been impli-
cated in a variety of solid tumors, including breast [7, 8],
melanoma [9], ovarian [10], and prostate [11, 12]. It was first
linked to T cell acute lymphoblastic leukemia (T-ALL),
where[50 % of tumors harbored activating mutations
within Notch1 [13, 14]. In contrast, reduced Notch signaling
has been implicated in HPV-positive cervical cancer [15],
neuroendocrine tumors [16], small cell lung cancer [17],
hepatocellular carcinoma [18], and skin squamous cell car-
cinoma [19]. Indeed, the use of gamma-secretase inhibitors
(GSIs) in clinical trials for Alzheimer’s Disease (the amyloid
precursor protein—APP—implicated in this disease is a
gamma-secretase target) showed an increase risk of skin
cancer development [20]; decreased gamma-secretase
activity is also associated with increased skin cancer occur-
rence in mice [21]. Therefore, the biological outcome/
function of Notch signaling as oncogenic or tumor-sup-
pressive is highly cell context specific (reviewed in [22]).
Inhibition of gamma-secretase has shown antitumor
effects in a variety of cancers in vitro and is thus consid-
ered an attractive pharmacology target. Pre-clinical reports
using cancer cell lines, patient samples in vitro, and in vivo
mouse models on the activity of MRK-003, a potent and
selective GSI, have reported Notch pathway inhibition and
antitumor activity in multiple myeloma [23], Non-Hodg-
kin’s leukemia [23], T-cell acute lymphoblastic leukemia
[24], breast cancer [25], pancreatic cancer [26, 27], lung
cancer [28], and glioblastoma [29].
Notch signaling plays a vital role in intestinal homeo-
stasis, self-renewal, and cell fate decisions during post-
development [30–34] and is activated in colorectal ade-
nocarcinomas [35, 36]. In theory, blocking Notch activa-
tion using GSIs might enhance chemotherapy effects for
the treatment of colon cancer. Here, we tested the capacity
for GSIs to synergize with oxaliplatin in colon cancer cell
lines and evaluated the underlying molecular mechanisms.
Surprisingly we show that GSIs blocked oxaliplatin-
induced apoptosis through increased protein levels of Mcl-
1 and/or Bcl-xL. Restoration of apoptosis was achieved by
blocking Mcl-1 and/or Bcl-xL with obatoclax or siRNA.
Materials and methods
Cell lines and chemicals
The human colorectal cancer cell lines HCT-116, HCT-15,
HT-29, and Colo205 were obtained from NCI; SW480 was
obtained from ATCC. All cell lines were grown in RPMI
1640 supplemented with 10 % FBS and L-glutamine and
grown in a 37 !C humidified camber 5 % CO2. Cells were
maintained for no more than 30 passages after thawing and
tested as mycoplasma-free. HCT-116 and SW480 cell lines
were authenticated using short tandem repeat (STR) DNA
typing according to ATCC’s ‘‘Authentication of Human
Cell Lines: Standardization of STR Profiling’’ (2012).
Oxaliplatin (Sigma) was suspended in 5 % dextrose.
The GSIs MRK-003 (a generous gift from Merck Inc),
DAPT (N-[N-(3,5-difluorophenacetyl-L-alanyl)-S-phenyl-
glycine]-t-butyl ester; Santa Cruz), GSI-XII (Calbio-
chem), and GSI-XX (DBZ; Calbiochem) and the Bcl-2
inhibitor obatoclax (GX15-070; Selleck) were suspended
in DMSO.
Apoptosis assays via flow cytometry
Apoptosis was measured by flow cytometry by detecting
activated Caspase-3 or by detecting Annexin-V. Cleaved
Caspase-3 was measured using the active caspase 3-FITC
Apoptosis Assay Kit (BD# 550480) according to the
manufacturer’s protocol. Data were acquired on a FACS
Scan or Calibur and analyzed with FlowJo software.
Apoptosis was also measured by AnnexinV-FITC (or
AnnexinV-APC) (BD# 556420 or 550475) and 7-AAD
staining according to the manufacturer’s protocol. Data
were acquired on a FACS Scan or Calibur and analyzed
with FlowJo software. Dot plots with the percentages of
each quadrant were reported for each sample.
Western blotting
Cell pellets were lysed in standard RIPA buffer (50 mMTris
pH 7.4, 150 mM NaCl, 1 % Igepal CA-630, 0.5 % sodium
deoxycholate, and 0.1 % SDS) containing protease and
phosphatase inhibitors—1 lg/ml each of aprotin, leupeptin,
and pepstatin and 1 mM each of sodium fluoride, sodium
vanadate, phenylmethylsulfonyl fluoride, and sodium pyro-
phosphate—for 30 min on ice. Cell extracts were clarified by
centrifugation at 15,0009g for 10 min at 4 !C. Protein
concentration was determined via the Bradford Assay and
lysates were mixed 1:1 in 29 Laemmeli Sample Buffer and
heated at 95 !C for 5 min. 30 lgof proteinwas resolved onto
SDS-PAGE gels and transferred onto PVDF membranes.
Membranes were blocked in 19 TBST (Tris buffered saline
with 0.05 % Tween-20) supplemented with 5 % milk and
primary antibodies were incubated overnight at 4 !C in 1 %
BSAor 5 %milk dissolved in TBST. The primary antibodies
used for western blot were: rabbit anti-Mcl-1 (#5453), rabbit
anti-Bcl-xL (#2764), and rabbit anti-PARP (#9542) from
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Cell Signaling; mouse anti-b-actin (#A5441) from Sigma.
Membranes were washed and incubated with peroxidase-
conjugated anti-mouse or anti-rabbit IgG secondary
antibodies (Jackson ImmunoReasearch Laboratories).
The signals were visualized using SuperSignal West
Pico Chemiluminescent detection reagent (Pierce/
ThermoScientific).
Cytochrome C release
Adherent and non-adherent cells were harvested by
scrapping and pelleted by centrifugation. For preparation of
cytosolic extracts, the cell pellet was immediately sus-
pended in a cytochrome c permeabilization buffer (20 mM
Hepes pH 7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA,
1 mM EGTA, 1 mM DTT, 250 mM Sucrose) containing
200 lg/ml Digitonin (Sigma# D141) supplemented with
protease and phosphatase inhibitors (see above in Western
blotting) and incubated on ice for 5 min. Lysates were
clarified by centrifugation at 1,0009g for 5 min at 4 !C to
remove unlysed cells, cell debris and nuclei. The super-
natant transferred to a new tube and centrifuged at
20,0009g for 20 min at 4 !C to remove mitochondria and
any remaining debris. The supernatant was transferred to a
new tube and 20–30 lg of protein was subjected to western
blot analysis using anti-cytochrome c (BD# 556433) anti-
body. An anti-COX IV (Cell Signaling# 4580) antibody
was used as a control to measure mitochondrial contami-
nation of cytosolic extracts.
Cell survival and colony formation assays
Short-term cell survival was measured by MTT assay.
Cells were seeded into 96-well plates in quadruplicate
and drug treated the next day for 48 h. MTT
((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) (Sigma# M2128) was added at a final concentration
of 0.5 lg/uL per well and incubated for 3–4 h in a
humidified chamber at 37 !C in the dark. The plate was
centrifuged, supernatant aspirated, 100 ll/well of DMSO
added, and the absorbance measured at 540 nm. Data
were normalized relative to untreated controls, which
were taken as 100 % survival.
Colony/foci formation assays were used to assess
long-term cell survival. Cells were seeded into 12-well
plates, allowed to attach overnight, and drug treated for
24 h. Attached cells were then trypsinized, counted, and
1,000 cells were plated in triplicate in 6-well plates and
allowed to grow for 8 or 12 days. Cells were fixed with
4 % paraformaldehyde for 15 min with 0.1 % crystal
violet.
Cell cycle analysis
Adherent and non-adherent cells were collected, fixed in
ice-cold 70 % ethanol, and kept at 4 !C overnight. Cells
were then stained with 20 lg/ml propidium iodine, 200 lg/
ml RNase A, and 0.1 % Triton X-100 in PBS for 30 min in
the dark at room temperature. Data was acquired on a
FACS Scan or Calibur and analyzed with ModFit software.
Activation of Bax and Bak
Cell pellets were lysed in CHAPS lysis buffer (1 %
CHAPS, 150 mM NaCl, 1 mM Hepes pH 7.4) containing
protease and phosphatase inhibitors (see above for details)
for 1 h on ice. Lysates were centrifuged and protein con-
centration was determined by Bradford assay. 500 lg of
protein was precleared with 20 ll of anti-mouse IgG
(whole molecule)-agarose beads (Sigma# A6531) for 1 h at
4 !C with rotation. The beads were pelleted and the
supernatant was transferred to a new tube. Activated Bax or
Bak was immunoprecipitated with 2 lg of anti-Bax 6A7
(Sigma# B8429) or anti-Bak Ab-1 (Calbiochem# AM03)
antibodies and 20 ll of anti-mouse IgG-agarose beads and
incubated overnight at 4 !C with rotation. The beads were
pelleted and washed three times in CHAPS lysis buffer
before being subjected western blot analysis with rabbit
anti-Bax (N-20, #sc-493) and rabbit anti-Bak (G-23, #sc-
832), respectively (Santa Cruz).
RNA interference
Small interfering RNA (siRNA) for Mcl-1 (#sc-35877),
Bcl-xL (#43630), and Control-A (#sc-37007) was pur-
chased from Santa Cruz. Cells were transfected with
RNAiMax (Invitrogen) with a reverse transfection protocol
according to the manufacturer’s protocol. Briefly, siRNA
and RNAiMax were incubated in serum-free RPMI 1640
for at least 20 min at room temperature. After siRNA:
RNAiMax complexes were allowed to form, diluted cells
in full serum media (RPMI 1640 ? 10 % FBS) were added
and the mixture plated out.
Results
Gamma-secretase inhibitors attenuate chemotherapy-
induced apoptosis of colon cancer cells
Oxaliplatin is the first line of chemotherapy for colon cancer.
We hypothesized that combining oxaliplatin with GSIs
would enhance chemosensitivity in colon cancer cell lines,
as others have shown using alternative GSIs [36–38].
To explore the role of gamma-secretase inhibition on
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oxaliplatin-induced apoptosis, two colon cancer cell lines—
HCT-116 and SW480—were treated with oxaliplatin in the
absence or presence of MRK-003 (Merck, Inc.), a potent
gamma-secretase inhibitor. Apoptosis wasmeasured by flow
cytometry using either Annexin-V with 7-AAD double
staining or measuring active caspase-3. The combination of
oxaliplatin andMRK-003 resulted in a reduction in apoptosis
by at least 50 % as measured by either Annexin-V and
7-AAD positivity (Fig. 1a) or activated caspase-3 (Fig. 1b)
in both cell lines compared to oxaliplatin alone. To confirm
that the resultswere likely due to gamma-secretase inhibition
and not an off target effect of MRK-003, the effect of alter-
native GSIs on apoptosis of oxaliplatin treated cells were
repeated using DAPT, GSI-XII, and GSI-XX (DBZ), widely
used and commercially available GSIs that are structurally
distinct from MRK-003. Both cell lines treated with DAPT
and GSI-XX showed apoptosis rates approximately half that
of oxaliplatin-treated cells (Supplemental Fig. 1a, c). The
gamma-secretase inhibitor GSI-XII showed a slight decrease
in oxaliplatin-induced apoptosis in SW480 but a slight
inductionwas observed inHCT-116 (Supplemental Fig. 1b).
MRK-003, DAPT, GSI-XII, or GSI-XX alone did not induce
apoptosis in either HCT-116 or SW480 (Fig. 1a, b, Supple-
mental Fig. 1a–c). We further tested the effect of MRK-003
on oxaliplatin-induced apoptosis in three additional colon
cancer cell lines to determine whether the reduction in
apoptosis was cell line specific. We found greater than 50 %
reduction of apoptosis in oxaliplatin-treated HT-29, HCT-
15, and Colo205 cells in the presence of MRK-003 (Sup-
plemental Fig. 2). To test if the attenuation of apoptosis was
specific to oxaliplatin, we assessed the effects of gamma-
secretase inhibition with either irinotecan or etoposide.
Again, we observed a reduction of apoptosis in HCT-116
with MRK-003 in combination with either irinotecan or
etoposide; no difference in apoptosis was observed in
SW480 (Fig. 1c). Taken together, these data suggest that
gamma-secretase inhibition attenuates apoptosis induced by
chemotherapeutic agents in colon cancer.
The combined use of oxaliplatin and MRK-003
increases long-term survival in vitro
We hypothesized the attenuation of apoptosis seen in cells
treated with oxaliplatin and MRK-003 might be due to
increased survival, as measured by MTT assay and cell
cycle analysis. HCT-116 and SW480 were treated for 48 h
with oxaliplatin with or without MRK-003 and survival
was measured by MTT assay. As expected, oxaliplatin
treatment decreased viability by approximately 60 % for
both cell lines; the combination of oxaliplatin and MRK-
003 showed no difference compared to oxaliplatin alone
(Fig. 2a). MRK-003 alone had no effect on viability
compared to vehicle in either cell line.
Cell cycle analysis showed oxaliplatin induced a G2-M
arrest in HCT-116 that remained unchanged with the
addition of MRK-003; the percentage of cells in G0/G1,
however, increased (21–32 %, respectively) (Fig. 2b).
Oxaliplatin arrested SW480 cells in S phase and no change
was observed with the addition of MRK-003 in the cell
cycle profile (Fig. 2b). MRK-003 alone increased the G0/
G1 fraction from 34 to 48 % in HCT-116.
Colony forming assays are a measure of long-term
survival. Cell death may be mediated through non-apop-
totic mechanisms or may be delayed. The combination of
oxaliplatin and MRK-003 remarkably enhanced colony
formation in both HCT-116 and SW480 when compared to
oxaliplatin treated alone (Fig. 2c). Collectively, the data
suggests that GSI enhances the survival of cells treated
with oxaliplatin.
Attenuation of the apoptotic signaling cascade
The mechanisms underlying gamma-secretase inhibition on
oxaliplatin-induced apoptosis was examined by evaluating
changes in the classical apoptotic signaling cascade. Cells
treated with oxaliplatin and MRK-003 blocked cleavage of
PARP (Fig. 3a) and caspase-3 (Fig. 1b) in both HCT116
and SW480 as measured by western blot and flow
cytometry, respectively. Caspase activity can be blocked
through direct interaction with the inhibitor of apoptosis
protein (IAP) family members c-IAP1, c-IAP2 and XIAP,
but no differences in protein levels were detected by
western blot (data not shown). Second, oxaliplatin-induced
cytochrome c release in both HCT-116 and SW480 was
blocked by the addition of MRK-003 (Fig. 3b).
Bax and Bak are the two key pro-apoptotic proteins that
regulate cytochrome c release. Bax and Bak are activated
by conformational changes to promote homo-oligomeri-
zation to create pore-like channels responsible for cyto-
chrome c release (reviewed in [39]). The activation of Bax
and Bak can be assessed using conformation specific
antibodies (6A7 for Bax and Ab-1 for Bak) [40]. To
determine if MRK-003 altered the activation of Bax and
Bak in oxaliplatin-treated cells, Bax and Bak were immu-
noprecipitated with their active conformation specific
antibodies and western blotted. In response to oxaliplatin,
both HCT-116 and SW480 show activation of Bax and
Bak, which was markedly inhibited in the presence of
MRK-003 (Fig. 3c).
Mcl-1 and Bcl-xL levels are elevated
in oxaliplatin?GSI treated cells
The activation of Bax and Bak can be prevented by the
anti-apoptotic Bcl-2 family member proteins Bcl-2,
Bcl-xL, Mcl-1, Bcl-w, and A1 [41]. Gamma-secretase
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inhibition has been shown to regulate protein expression of
the Bcl-2 family members [23, 42]. We tested whether or
not GSI treatment altered total protein levels of Mcl-1 or
Bcl-xL (neither cell line expressed detectable levels of Bcl-
2, data not shown). Cells treated with MRK-003 alone
increased Mcl-1 protein levels without seemingly affecting
Bcl-xL levels in both HCT-116 and SW480 (Fig. 4). The
combination of oxaliplatin and MRK-003 lead to enhanced
protein levels of both Mcl-1 and Bcl-xL as compared to
oxaliplatin alone in both cell lines.
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Fig. 1 Gamma-secretase inhibition attenuates oxaliplatin-induced
apoptosis. HCT-116 and SW480 cells were treated with 15 lM
(HCT-116) or 30 lM (SW480) oxaliplatin (Oxa) for 48 h in the
absence or presence of 10 lM (HCT-116) or 5 lM (SW480) MRK-
003 (GSI). Apoptosis rates were measure by flow cytometry following
Annexin-V/7-AAD staining (a) and active caspase-3 labeling (b).
c HCT-116 and SW480 were treated with either 50 lM Etoposide or
50 lM Irinotecan in the absence or presence of 10 lM (HCT-116) or
5 lM (SW480) MRK-003 for 48 h. Apoptosis rates were measured
by flow cytometry following active caspase-3 reactivity. Represented
data are mean ± SEM of three (a, b) or two (c) independent
experiments
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Knockdown or pharmacologic inhibition of Mcl-1 and/
or Bcl-xL restores apoptosis in cells treated
with oxaliplatin and MRK-003
To examine whether the MRK-003 induced increase in the
anti-apoptotic proteins Mcl-1 and/or Bcl-xL is responsible
for decreased sensitivity to oxaliplatin treatment, we used
RNAi interference (siRNA) assays to silence Mcl-1 and/or
Bcl-xL. A dose-dependent knockdown of Mcl-1 resulted in
a dose dependent increase in apoptosis in HCT-116 cells
treated with oxaliplatin and MRK-003 but had no effect
with MRK-003 alone as measured by flow cytometry for
active caspase-3 (Fig. 5a). Reduction of Bcl-xL levels in
HCT-116 produced a similar dose dependent increase in
apoptosis in cells treated with both oxaliplatin and MRK-
003 (Fig. 5b). As expected, reducing levels of Mcl-1
or Bcl-xL lead to increased sensitivity to oxaliplatin.
Knockdown of Mcl-1 and Bcl-xL levels were confirmed by
western blot. Reducing the levels of both Bcl-xL and Mcl-1
with low picomolar doses greatly increased oxaliplatin-
induced apoptosis which was not inhibited with the addi-
tion of MRK-003 (Fig. 5c).
To further confirm the role of Mcl-1 and Bcl-xL in medi-
ating the abrogation of oxaliplatin-induced apoptosis by
MRK-003, we used the BH3-peptide mimetic obatoclax
(GX15-070) to broadly antagonize Bcl-2 pro-survival family
members Mcl-1 and Bcl-xL. Apoptosis inhibition associated
with the combination of oxaliplatin and MRK-003 treatment
was reversed with the addition of obatoclax in both HCT-116
(Fig. 6a) and SW480 (Fig. 6b). Of note, the combination of
MRK-003 and obatoclax also resulted in an increase in
apoptosis inHCT-116 (Fig. 6a). Thus, inhibitingMcl-1 and/or
Bcl-xL through RNA interference or small molecule inhibitor
(obatoclax) lead to a restoration of apoptosis in colon cancer.
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Fig. 2 Oxaliplatin and MRK-003 increases long-term survival. HCT-
116 and SW480 cells were treated with 15 lM (HCT-116) or 30 lM
(SW480) Oxa for 48 h in the absence or presence of 10 lM (HCT-
116) or 5 lM (SW480) MRK-003. After treatment, MTT for viability
(a) or cell cycle analysis (b) was performed. Represented data are
mean ± SEM of three independent experiments. c Colony/Foci
formation assays on HCT-116 and SW480 cells treated with 1 lM
Oxa in the absence or presence of MRK-003 (10 lM for HCT-116,
5 lM for SW480) for 24 h. Results were repeated twice with similar
results
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Discussion
In this study, we report that the combination of the gamma-
secretase inhibitor MRK-003 with oxaliplatin elicited
potent chemoresistance in colon cancer cells by greatly
decreasing apoptosis and leading to increased long-term
survival. We showed the combination of oxaliplatin and
MRK-003 reduced apoptosis in HCT-116, SW480, HT-15,
HT-29, and Colo205 colon cancer cell lines by at least half.
The reduction in apoptosis could be replicated using
alternative GSIs (DAPT and GSI-XX) in HCT-116 and
SW480. GSI-XII, a fourth GSI used in this study, slightly
increased apoptosis by 10 % in HCT-116 and only
decreased apoptosis by approximately 7 % in SW480.
None of the four GSIs used in this study elicited apoptosis
by themselves. When MRK-003 was combined with other
chemotherapeutic agents (etoposide and irinotecan),
decreased apoptosis was also seen in HCT-116. MRK-003,
however, had no effect on apoptosis of etoposide- or iri-
notecan-treated SW480 cells, a finding reported elsewhere
using DAPT in combination with various chemotherapeutic
agents [38]. These data suggest that the effects seen are not
cell-context specific, mediated by gamma-secretase inhi-
bition (not an off-target effect), and not unique to oxa-
liplatin treatment. We observed no change in viability in
oxaliplatin-treated cells with or without MRK-003 in either
HCT-116 or SW480. Cell cycle analysis showed a slight
increase in G0/G1 arrest with the addition of MRK-003 in
oxaliplatin-treated HCT-116 cells alone (no change was
observed in SW480). These data do not account for the
reduction in apoptosis seen with MRK-003 treatment.
However, to further support the decrease in apoptosis
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Fig. 3 The combination of
oxaliplatin and MRK-003
reduces Bax and Bak activation,
cytochrome c release, and
PARP cleavage. HCT-116 and
SW480 cells were treated with
15 lM (HCT-116) or 30 lM
(SW480) for 48 h in the absence
or presence of 10 lM (HCT-
116) or 5 lM (SW480) MRK-
003. a Full-length (110 kDa)
and cleaved (80 kDa) PARP
was analyzed by western
blotting of whole cell lysates.
Equal protein loading was
shown by probing for beta-actin.
b Release of cytochrome c into
cytosolic fraction was analyzed
by western blot. Potential
mitochondrial contamination
was detected by COX-IV
(positive control lane is a whole
cell extract). Beta-actin was
used as a loading control.
c Immunoprecipitation of active
Bax and Bak. Whole cell
extracts were probed for total
Bax, total Bak, and beta-actin
Apoptosis
123
Author's personal copy
  117 
observed in oxaliplatin and MRK-003 treated cell, long-
term survival assays showed increased cell survival in
combination treatment compared to oxaliplatin alone.
We identified increased protein levels of the anti-apoptotic
Bcl-2 family members Mcl-1 and Bcl-xL in response to
MRK-003 as pivotal players responsible for decreased oxa-
liplatin-induced apoptosis, leading to a reduction of Bax and
Bak activation and downstream suppression of the apoptotic
cascade (cytochrome c release, caspase-3 cleavage, and
PARP cleavage). Restoration of apoptosis was achieved by
blocking Mcl-1 and/or Bcl-xL through RNA interference or
theMcl-1/Bcl-xL/Bcl-2 antagonist obatoclax. Knockdown of
Mcl-1 and/or Bcl-xL, however, did not induce apoptosis upon
GSI treatment alone but the combination of GSI and oba-
toclax did in HCT-116. From these data, we conclude that
increased protein levels of Mcl-1 and/or Bcl-xL are respon-
sible for the attenuation of oxaliplatin-induced apoptosis
observed upon MRK-003 treatment.
Several studies have highlighted the role of Notch sig-
naling in the regulation of Mcl-1 and Bcl-xL. Mcl-1 levels
are decreased by blocking the Notch pathway via a GSI [42]
or with small-interfering RNA [43] and increased by over-
expression of NICD [42]. GSIs have been shown to increase
Noxa, a pro-survival BH3-only protein that promotes Mcl-1
degradation [44, 45]. Likewise, blocking Notch signaling
can decrease Bcl-xL levels [27, 44]. In contrast, our data
shows increased protein levels of Mcl-1 and Bcl-xL upon
GSI treatment. This phenomena has been replicated by Liu
et al. [46] in T-ALL cell lines when examining the effect of
gamma-secretase inhibition on chemosensitivity. One subset
of cells exhibited enhancement of apoptosis while another
subset showed resistance via upregulation of Bcl-xL. The
mechanism by which this occurs is still not well defined.
Our data also conflicts with other reports in the litera-
ture showing synergism between cytotoxic agents and
GSIs in colon cancer cell lines. One study showed that
blocking Notch-1 signaling using GSI34 (a novel gamma-
secretase inhibitor) lead to an enhancement of oxaliplatin
sensitivity [36]. Alternatively, DAPT sensitized colon
cancer cell lines SW480 and DLD-1 to paclitaxel only but
not 5-FU, camptothecin, TRAIL, or cisplatin [38]. A third
group tested the effects of GSI-XX (DBZ), another GSI, in
combination with platinum compounds (cisplatin, carbo-
platin, and oxaliplatin) on a panel of 20 human colon
cancer cell lines [37]. GSI-XX alone had no effect on cell
survival and, in combination with cisplatin, only a subset
exhibited some degree of increased cell death; a few cell
lines sensitive to the combination of cisplatin and GSI-XX
showed no effect with oxaliplatin or carboplatin. In our
hands, gamma-secretase inhibition using MRK-003,
DAPT, or GSI-XX abrogated oxaliplatin-induced apop-
tosis via increased Mcl-1 and/or Bcl-xL protein levels, as
seen by Liu et al. [46]. The pleotropic nature of gamma-
secretase inhibition on chemotherapy-induced apoptosis is
not well understood. It likely could be a reflection of
complex context-dependent signaling downstream of the
Notch pathway, and thus may only be of clinical utility to
a particular (as yet undefined) subtype of colorectal
cancer.
The observed effects of MRK-003, DAPT, and GSI-XX
on attenuating chemotherapy-induced apoptosis may not be
caused by Notch inhibition but rather differential targeting
of other known gamma-secretase substrates. Gamma-
secretase primarily catalyzes the intramembranous cleav-
age of Notch and APP. However, it has also been shown to
target at least a dozen known type I transmembrane pro-
teins, including E-cadherin, ErbB4, CD44, and c-Met, but
their mechanism and function is not well studied (for
review, see [47]). Also, the specificity of GSIs for different
substrates may drive the discrepancies found in the litera-
ture, thus it will be important to understand the biochem-
ical differences between specific GSIs, particularly since
we showed that GSI-XII did not have the same effect as the
other three GSIs. While we used four commercially
available inhibitors known to block both Notch cleavage
and activity as well as induce apoptosis in multiple tumor
cell lines, we cannot rule out the possibility that these GSIs
may also indirectly target other molecular pathways, such
as pro-apoptotic signaling pathways, which may outweigh
or antagonize any pro-apoptotic effects conferred by
reduced Notch signaling in colon cancer cells. Therefore,
the contribution of single, combinatorial, or complete
ablation of all four Notch receptors on chemosensitivity is
needed to address these concerns. The newly emerging
neutralizing antibodies to individual Notch receptors will
surely help to answer this question.
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Fig. 4 MRK-003 increases protein expression of Mcl-1 and Bcl-xL.
HCT-116 and SW480 cells were treated with 15 lM (HCT-116) or
30 lM (SW480) for 48 h in the absence or presence of 10 lM (HCT-
116) or 5 lM (SW480) MRK-003. Total levels of Mcl-1 and Bcl-xL
were assessed by immunoblotting. Beta-actin was used as a protein
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Standard chemotherapy approaches may need to be
modified to include other novel inhibitors. Despite the
apparent discrepancies of gamma-secretase inhibition on
chemosensitivity, we were able to restore the attenuation of
oxaliplatin-induced apoptosis seen with MRK-003 by
antagonizing Mcl-1 and/or Bcl-xL. Combining GSIs and
chemotherapy with an anti-apoptotic Bcl-2 family member
agonist like obatoclax may be a valid therapeutic approach.
We also found enhanced apoptosis with MRK-003 and
obatoclax combined. Previous studies have shown sensiti-
zation with the combination of GSIs and the BH3 mimetic
ABT-737 (antagonizes Bcl-2/Bcl-xL/Bcl-w but not Mcl-1
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Fig. 5 Knockdown of Mcl-1 and/or Bcl-xL rescues MRK-003
attenuation of oxaliplatin-induced apoptosis. a HCT-116 was trans-
fected with increasing amounts of Mcl-1 siRNA as indicated for 24 h.
Cells were then treated with 15 lM Oxa in the absence or presence of
10 lM MRK-003 for 48 h. Western blot shows efficiency of Mcl-1
knockdown. b HCT-116 was transfected with increasing amounts of
Bcl-xL siRNA as indicated for 24 h. Cells were then treated with
15 lM Oxa in the absence or presence of 10 lM MRK-003 for 48 h.
Western blot shows efficiency of Bcl-xL knockdown. c HCT-116 was
transfected with 250 pM Mcl-1 and 25 pM Bcl-xL siRNA as
indicated for 24 h. Cells were then treated with 15 lM Oxa in the
absence or presence of 10 lM MRK-003 for 48 h. Apoptosis rates
were measure by flow cytometry following active caspase-3 reactiv-
ity. Represented data are mean ± SEM of two independent
experiments
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[48]) in GSI-sensitive cell lines where GSI alone increased
Noxa levels, leading to subsequent Mcl-1 degradation [45,
49]. Our data shows MRK-003 synergism with obatoclax in
GSI-resistant colon cancer cell lines where GSI alone
increases Mcl-1 and Bcl-xL levels. Therefore, combining
GSIs with other targeted therapeutics instead of chemo-
therapy may be a more effective strategy in the treatment
of colorectal cancer.
To our knowledge, the only published Phase II clinical
trial studying the efficacy of gamma-secretase inhibitor—
RO4929097—monotherapy in metastatic colorectal cancer
patients demonstrated no antitumor effects [50]. Never-
theless, there are multiple clinical trials investigating
mono- and combination therapies involving GSIs in a wide
variety of tumors (www.clinicaltrials.gov). The results
posed here do not diminish the potential use of GSIs in a
clinical setting but rather suggest caution when developing
drug combinations. First, further detailed mechanistic
studies looking at the biochemical differences in substrate
specificity and potential off-target effects of the many
available GSIs are needed. Also, the effects of gamma-
secretase inhibition in relation to cell context and interac-
tions with signaling pathways needs further clarification as
there are clear indications that GSIs can have opposing
effects even in same tumor types. Third, the potential still
exists for using GSIs in combination with other therapeutic
agents to elicit anti-tumorigenic responses. Our results
provide a cautionary tale for broad application of GSIs.
Understanding the actions of this drug when used in
combination with standard chemotherapy and/or targeted
therapies will provide greater knowledge of its potential
use for a personalized approach to cancer treatment.
Acknowledgments This work has been supported in part by the Flow
Cytometry Core Facility at the H. Lee Moffitt Cancer Center &
Research Institute, a comprehensive cancer center designated by the
National Cancer Institute. This work was supported by Bankhead-
HCT-116
0
5
10
15
20
25
30
35
40
V GSI Obx GSI + Obx Oxa Oxa + Obx Oxa + GSI Oxa + GSI + Obx
%
 A
po
pt
os
is  
SW480
0
5
10
15
20
25
30
35
40
V GSI Obx GSI + Obx Oxa Oxa + Obx Oxa + GSI Oxa + GSI + Obx
%
 A
po
pt
os
is
 
 
A
B
Fig. 6 Obatoclax rescues MRK-003 attenuation of Oxaliplatin-
induced apoptosis. a HCT-116 was treated with 15 lM Oxa in the
absence or presence of 10 lM MRK-003 and/or 75 nM obatoclax
(Obx) for 48 h. b SW480 was treated with 30 lM Oxa in the absence
or presence of 5 lM MRK-003 and/or 25 nM obatoclax for 48 h.
Apoptosis rates were measured by flow cytometry following active
caspase-3 reactivity. Represented data are mean ± SEM of at least
two independent experiments
Apoptosis
123
Author's personal copy
  120 
Coley Biomedical Research Program, Florida Department of Health,
Grant number 08BR-02 and by institutional funds from the Moffitt
Cancer Center (to T.J.Y.).
Conflict of interest No potential conflicts of interest.
References
1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012.
Cancer J Clin 62 (1):10–29. doi:10.3322/caac.20138
2. Saltz LB (2009) Looking ahead: what will change in colorectal
cancer treatment? Gastrointest Cancer Res 3(2 Suppl):S16–S18
3. Garcia-Foncillas J, Diaz-Rubio E (2010) Progress in metastatic
colorectal cancer: growing role of cetuximab to optimize clinical
outcome. Clin Transl Oncol 12(8):533–542
4. Schroeter EH, Kisslinger JA, Kopan R (1998) Notch-1 signalling
requires ligand-induced proteolytic release of intracellular
domain. Nature 393(6683):382–386. doi:10.1038/30756
5. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A
(1995) Signalling downstream of activated mammalian Notch.
Nature 377(6547):355–358. doi:10.1038/377355a0
6. Borggrefe T, Oswald F (2009) The Notch signaling pathway:
transcriptional regulation at Notch target genes. Cell Mol Life Sci
66(10):1631–1646. doi:10.1007/s00018-009-8668-7
7. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready
DR, Lockwood G, Egan SE (2005) High-level coexpression of
JAG1 and NOTCH1 is observed in human breast cancer and is
associated with poor overall survival. Cancer Res 65(18):8530–
8537. doi:10.1158/0008-5472.CAN-05-1069
8. Stylianou S, Clarke RB, Brennan K (2006) Aberrant activation of
notch signaling in human breast cancer. Cancer Res 66(3):
1517–1525. doi:10.1158/0008-5472.CAN-05-3054
9. BedogniB,Warneke JA,NickoloffBJ,GiacciaAJ, PowellMB(2008)
Notch1 is an effector of Akt and hypoxia in melanoma development.
J Clin Invest 118(11):3660–3670. doi:10.1172/JCI36157
10. Wang M, Wang J, Wang L, Wu L, Xin X (2010) Notch1
expression correlates with tumor differentiation status in ovarian
carcinoma. Med Oncol 27(4):1329–1335. doi:10.1007/s12032-
009-9384-8
11. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD,
Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM, Rubin
MA, Aster JC (2004) JAGGED1 expression is associated with
prostate cancer metastasis and recurrence. Cancer Res 64(19):
6854–6857. doi:10.1158/0008-5472.can-04-2500
12. Wang Z, Li Y, Banerjee S, Kong D, Ahmad A, Nogueira V, Hay N,
Sarkar FH (2010) Down-regulation of Notch-1 and Jagged-1
inhibits prostate cancer cell growth, migration and invasion, and
induces apoptosis via inactivation of Akt, mTOR, and NF-jB
signaling pathways. J Cell Biochem 109(4):726–736. doi:10.1002/
jcb.22451
13. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith
SD, Sklar J (1991) TAN-1, the human homolog of the Drosophila
notch gene, is broken by chromosomal translocations in T lym-
phoblastic neoplasms. Cell 66(4):649–661
14. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB,
Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC (2004)
Activating mutations of NOTCH1 in human T cell acute lym-
phoblastic leukemia. Science 306(5694):269–271. doi:10.1126/
science.1102160
15. Talora C, Sgroi DC, Crum CP, Dotto GP (2002) Specific down-
modulation of Notch1 signaling in cervical cancer cells is
required for sustained HPV-E6/E7 expression and late steps of
malignant transformation. Genes Dev 16(17):2252–2263. doi:10.
1101/gad.988902
16. Kunnimalaiyaan M, Chen H (2007) Tumor suppressor role of
Notch-1 signaling in neuroendocrine tumors. Oncologist
12(5):535–542. doi:10.1634/theoncologist.12-5-535
17. Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD,
Baylin SB, Ball DW (2001) Notch signaling induces cell cycle
arrest in small cell lung cancer cells. Cancer Res 61(7):3200–3205
18. Qi R, An H, Yu Y, Zhang M, Liu S, Xu H, Guo Z, Cheng T, Cao
X (2003) Notch1 signaling inhibits growth of human hepatocel-
lular carcinoma through induction of cell cycle arrest and apop-
tosis. Cancer Res 63(23):8323–8329
19. Lefort K, Mandinova A, Ostano P, Kolev V, Calpini V, Kolf-
schoten I, Devgan V, Lieb J, Raffoul W, Hohl D, Neel V, Garlick
J, Chiorino G, Dotto GP (2007) Notch1 is a p53 target gene
involved in human keratinocyte tumor suppression through neg-
ative regulation of ROCK1/2 and MRCKalpha kinases. Genes
Dev 21(5):562–577. doi:10.1101/gad.1484707
20. McKee S (2010) Lilly hit by spectacular failure of phase III
Alzheimer’s candidate. PharmaTimes. http://www.pharmatimes.
com/Article/10-08-18/Lilly_hit_by_spectacular_failure_of_Phase_
III_Alzheimer_s_candidate.aspx-.UA2YKRZFENo.link. Accessed
May 2012
21. Li T, Wen H, Brayton C, Laird FM, Ma G, Peng S, Placanica L,
Wu TC, Crain BJ, Price DL, Eberhart CG, Wong PC (2007)
Moderate reduction of gamma-secretase attenuates amyloid bur-
den and limits mechanism-based liabilities. J Neurosci 27(40):
10849–10859. doi:10.1523/jneurosci.2152-07.2007
22. Leong KG, Karsan A (2006) Recent insights into the role of
Notch signaling in tumorigenesis. Blood 107(6):2223–2233. doi:
10.1182/blood-2005-08-3329
23. Ramakrishnan V, Ansell S, Haug J, Grote D, Kimlinger T,
Stenson M, Timm M, Wellik L, Halling T, Rajkumar SV, Kumar
S (2012) MRK003, a [gamma]-secretase inhibitor exhibits
promising in vitro pre-clinical activity in multiple myeloma and
non-Hodgkin’s lymphoma. Leukemia 26(2):340–348
24. Lewis HD, Leveridge M, Strack PR, Haldon CD, O’Neil J, Kim
H, Madin A, Hannam JC, Look AT, Kohl N, Draetta G, Harrison
T, Kerby JA, Shearman MS, Beher D (2007) Apoptosis in T cell
acute lymphoblastic leukemia cells after cell cycle arrest induced
by pharmacological inhibition of notch signaling. Chem Biol
14(2):209–219. doi:10.1016/j.chembiol.2006.12.010
25. Grudzien P, Lo S, Albain KS, Robinson P, Rajan P, Strack PR,
Golde TE, Miele L, Foreman KE (2010) Inhibition of Notch
signaling reduces the stem-like population of breast cancer cells
and prevents mammosphere formation. Anticancer Res 30(10):
3853–3867
26. Plentz R, Park JS, Rhim AD, Abravanel D, Hezel AF, Sharma
SV, Gurumurthy S, Deshpande V, Kenific C, Settleman J, Ma-
jumder PK, Stanger BZ, Bardeesy N (2009) Inhibition of gamma-
secretase activity inhibits tumor progression in a mouse model of
pancreatic ductal adenocarcinoma. Gastroenterology 136 (5):
1741–1749.e1746
27. Vo K, Amarasinghe B, Washington K, Gonzalez A, Berlin J,
Dang TP (2011) Targeting notch pathway enhances rapamycin
antitumor activity in pancreas cancers through PTEN phosphor-
ylation. Mol Cancer 10:138. doi:10.1186/1476-4598-10-138
28. Konishi J, Kawaguchi KS, Vo H, Haruki N, Gonzalez A, Carbone
DP, Dang TP (2007) Gamma-secretase inhibitor prevents Notch3
activation and reduces proliferation in human lung cancers.
Cancer Res 67(17):8051–8057. doi:10.1158/0008-5472.can-07-
1022
29. Chen J, Kesari S, Rooney C, Strack PR, Chen J, Shen H, Wu L,
Griffin JD (2010) Inhibition of Notch signaling blocks growth of
glioblastoma cell lines and tumor neurospheres. Genes Cancer
1(8):822–835. doi:10.1177/1947601910383564
30. Riccio O, van Gijn ME, Bezdek AC, Pellegrinet L, van Es JH,
Zimber-Strobl U, Strobl LJ, Honjo T, Clevers H, Radtke F (2008)
Apoptosis
123
Author's personal copy
  121 
Loss of intestinal crypt progenitor cells owing to inactivation of
both Notch1 and Notch2 is accompanied by derepression of CDK
inhibitors p27Kip1 and p57Kip2. EMBO Rep 9(4):377–383.
doi:10.1038/embor.2008.7
31. Sander GR, Powell BC (2004) Expression of notch receptors and
ligands in the adult gut. J Histochem Cytochem 52(4):509–516
32. Fre S, Huyghe M, Mourikis P, Robine S, Louvard D, Artavanis-
Tsakonas S (2005) Notch signals control the fate of immature
progenitor cells in the intestine. Nature 435(7044):964–968.
doi:10.1038/nature03589
33. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M,
Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers
H (2005) Notch/gamma-secretase inhibition turns proliferative
cells in intestinal crypts and adenomas into goblet cells. Nature
435(7044):959–963. doi:10.1038/nature03659
34. Radtke F, Clevers H (2005) Self-renewal and cancer of the gut:
two sides of a coin. Science 307(5717):1904–1909. doi:10.1126/
science.1104815
35. Reedijk M, Odorcic S, Zhang H, Chetty R, Tennert C, Dickson
BC, Lockwood G, Gallinger S, Egan SE (2008) Activation of
Notch signaling in human colon adenocarcinoma. Int J Oncol
33(6):1223–1229
36. Meng RD, Shelton CC, Li Y-M, Qin L-X, Notterman D, Paty PB,
Schwartz GK (2009) c-Secretase inhibitors abrogate oxaliplatin-
induced activation of the Notch-1 signaling pathway in colon
cancer cells resulting in enhanced chemosensitivity. Cancer Res
69(2):573–582. doi:10.1158/0008-5472.can-08-2088
37. Aleksic T, Feller S (2008) Gamma-secretase inhibition combined
with platinum compounds enhances cell death in a large subset of
colorectal cancer cells. Cell Commun Signal 6(1):8
38. Akiyoshi T, Nakamura M, Yanai K, Nagai S, Wada J, Koga K,
Nakashima H, Sato N, Tanaka M, Katano M (2008) Gamma-
secretase inhibitors enhance taxane-induced mitotic arrest and
apoptosis in colon cancer cells. Gastroenterology 134(1):131–
144. doi:10.1053/j.gastro.2007.10.008
39. Tait SWG, Green DR (2010) Mitochondria and cell death: outer
membrane permeabilization and beyond. Nat Rev Mol Cell Biol
11(9):621–632
40. Hsu Y-T, Youle RJ (1998) Bax in murine thymus is a soluble
monomeric protein that displays differential detergent-induced
conformations. J Biol Chem 273(17):10777–10783. doi:10.1074/
jbc.273.17.10777
41. Brunelle JK, Letai A (2009) Control of mitochondrial apoptosis
by the Bcl-2 family. J Cell Sci 122(4):437–441. doi:10.1242/jcs.
031682
42. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF,
White RR, Rich JN, Sullenger BA (2010) Notch promotes
radioresistance of glioma stem cells. Stem Cells 28(1):17–28.
doi:10.1002/stem.261
43. Zhao N, Guo Y, Zhang M, Lin L, Zheng Z (2010) Akt-mTOR
signaling is involved in Notch-1-mediated glioma cell survival
and proliferation. Oncol Rep 23(5):1443–1447
44. Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich
DI (2008) Inhibition of Notch signaling induces apoptosis of
myeloma cells and enhances sensitivity to chemotherapy. Blood
111(4):2220–2229. doi:10.1182/blood-2007-07-102632
45. Seveno C, Loussouarn D, Brechet S, Campone M, Juin P, Barille-
Nion S (2012) Gamma-secretase inhibition promotes cell death,
Noxa upregulation, and sensitization to BH3 mimetic ABT-737
in human breast cancer cells. Breast Cancer Res 14(3):R96.
doi:10.1186/bcr3214
46. Liu S, Breit S, Danckwardt S,Muckenthaler MU, Kulozik AE (2009)
Downregulation of Notch signaling by gamma-secretase inhibition
can abrogate chemotherapy-induced apoptosis in T-ALL cell lines.
Ann Hematol 88(7):613–621. doi:10.1007/s00277-008-0646-x
47. Haapasalo A, Kovacs DM (2011) The many substrates of
presenilin/c-secretase. J Alzheimers Dis 25(1):3–28. doi:10.3233/
jad-2011-101065
48. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri
DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ,
Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C,
Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O’Connor JM,
Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson
CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW,
Rosenberg SH (2005) An inhibitor of Bcl-2 family proteins
induces regression of solid tumours. Nature 435(7042):677–681
49. Li M, Chen F, Clifton N, Sullivan DM, Dalton WS, Gabrilovich DI,
Nefedova Y (2010) Combined inhibition of Notch signaling and
Bcl-2/Bcl-xL results in synergistic antimyeloma effect. Mol Cancer
Ther 9(12):3200–3209. doi:10.1158/1535-7163.mct-10-0372
50. Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han
G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D (2012) A
phase II study of RO4929097 in metastatic colorectal cancer. Eur
J Cancer 48(7):997–1003. doi:10.1016/j.ejca.2012.02.056
Apoptosis
123
Author's personal copy
  
ABOUT THE AUTHOR 
 Cindy Timme attended Rutgers, the State University of New Jersey in New 
Brunswick, NJ, USA from 2002-2006 where she obtained her Bachelor of Arts degree in 
Genetics.  There, she worked in the laboratory of Dr. Michael Hampsey her last year 
studying the ubiquitin pathway in phosphate uptake and metabolism in Saccharomyces 
cerevisiae.  After graduation, she entered the Cancer Biology Ph.D. program at the 
Moffitt Research Institute and the University of South Florida.  At Moffitt, she joined the 
laboratory of Dr. Timothy Yeatman and completed her dissertation work in the field of 
experimental therapeutics.  Her work focused on evaluating the validity of gamma-
secretase inhibitors to treat colorectal cancer. 
